Literator

1. Abraham KR, Kulhara P (1987) The efficacy of electroconvulsive therapy in the treatment of schizophrenia. Br J Psychiatry 151: 152-155

2. Adler LA, Angrist B, ReiterS, RotrosenJ (1989) Neuroleptic-induced akathisia: a review. Psychopharmacology 97: 1-11

3. Ahlfors UG, Baastrup PC, Dencker SJ, Elgen K, Lingjaerde 0, Pedersen Y, Schon U, Aaskoven 0 (1981) Flupenthixol decanoate in recurrent manic­depressive illness. Acta Psychiatr Scand 64: 226-237

4. Aldenhoff JB, Lux HD (1984) Lithium und kalziumabhangige Zellfunktionen. Der Beitrag eines membranphysiologischcn Untcrsuchungsansatzes zur Erklarung therapeutischer Lithiumwirkungen. Fortschr Neurol Psychiatr 52: 152-163

5. Amaducci L, Angst J, Bech P, Benkert 0, Bruinvcls J, Engel RR, Gottfries CG, Hippius H, Levy R, Lingjaerde 0, Lopez-Ibor JJ jr, Orgogozo JM, Pull C, Saletu B, Stoll KD, Woggon B (1990) Consensus conference on the methodo­logy of clinical trials of "nootropics", Munich, June 1989. Pharmacopsychiatry 23: 171-175

6. Amsterdam J, Brunswick D, Mendels J (1980) The clinical application of tri­cyclic antidepressant pharmacokinetics and plasma levels. Am J Psychiatry 153: 653-{)62

7. Amsterdam JD, Berwish NJ (1989) High dose tranylcypromine therapy for re­fractory depression. Pharmacopsychiatry 22: 21-25

7 a. Andersen PH, Gingrich JA, Bates MD, Dearry A, Falardeau P, Sen ogles SE, Cavon MG (1990) Dopamie receptor subtypes: beyond the DlID2 classifica­tion. Trends Pharmacol Sci 11: 231-236

8. Andreasen NC (1990) Positive and negative symptoms: historical and concep­tual aspects. Mod Probl Pharmacopsychiatry 24: 1-42

9. Andreasen NC, Olsen SA (1982) Negative vs positive schizophrenia: defini­tion and validation. Arch Gen Psychiatry 39: 789-794

10. Athen D (1986) Comparative investigation of chlormethiazole and neurolep­tic agents in the treatment of aleoholic delirium. Acta Psychiatr Scand 73 (SuppI329): 167-170

11. Avissar S, Schreiber G, Danon A, Belmaker RH (1988) Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 331: 440-442

12. Awouters F, Niemegeers CJE, Megens AAMp, Meert TF, Janssen PAJ (1988)

390 Literatur

The pharmacological profile of ritanserin, a very specific central serotonin S2 antagonist. Drug Dev Res IS: 61-73

13. Ayd FJ jr. (1989) Malpractice Suits and Tardive Dyskinesia. Int Drug Ther Newsl 24: 26--28

14. Baldessarini RJ (1984) Treatment of depression by altering monoamine mcta­bolism: Precursors and metabolic inhibitors. Psychopharmacol Bull 20: 224-239

15. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 179-191

16. Ballenger JC (1988) The clinical use of carbamazepinc in affective disorders. ] Clin Psychiatry 49 (SuppI4): 13-19

17. Baraban JM, Worley PF, Snyder SH (1989) Second messenger systems and psychoactivc drug action: focus on the phosphoinositide system and lithium. Am J Psychiatry 146: 1251-1260

18. Barlow DH (1988) Anxiety and its disorders. Guilford, New York 19. Barnes TRE (1988) Tardive dyskinesia: Risk factors, pathophysiology and

treatment. In: Granville-Grossman K (ed) Recent advances in clinical psy­chiatry, vol. 6. Churchill Livingstone, London, pp 185-207

20. Bauer MS, Whybrow PC (1990) Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a prelimi­nary study. Arch Gen Psychiatry 47: 435--440

21. Bauer MS, Whybrow Pc' Winokur A (1990) Rapid cycling bipolar affective disorder. 1. Association with grade I hypothyroidism. Arch Gen Psychiatry 47: 427--432

22. Bebbington PE, Kuipers L (1987) Non-physical treatment of the psychoses. Br Med Bull 43: 704-713

23. Beck AT, Rush AJ, Shaw BF, Emery G (1979) Kognitive Therapie der De­pression. Dt. Ausgabe hrsg. v. M. Hautzinger. 2. Auf]. 1986. Urban & Schwar­zenberg, Miinchen

24. Beckham EE (1990) Psychotherapy of depression. Research at a crossroads: Directions for the I 990s. Clinical Psychol Rev 10: 207-228

25. Belmaker RH (1984) Adenylate cyclase and the search for new compounds with the clinical profile of lithium. Pharmacopsychiatria 17: 9-15

26. Benkert ° (1990) Functional classification and response to psychotropic drugs. In: Benkert 0, Maier W, Rickels K (cds) Methodology of the evalu­ation of psychotropic drugs. Springer, Berlin Heidelberg pp 155-163

27. Benkert ° (1990) Zum Wandel in der psychiatrischcn Pharmakotherapie. In: Lungershausen E, Kaschka WP, Witkowski RJ (Hrsg) Affektive Psychosen. Schattauer, Stuttgart S 529-532

28. Benkert 0, Holsboer F (1984) Effect of sulpiride in endogenous depression. Acta Psychiatr Scand [Suppl 311]69: 43--48

29. Berlant JL (1986) Neuroleptics and reserpine in refractory psychoses. J Clin Psychopharmacol 6: 180--184

30. Berridge MJ, Downes CP, Hanley MR (1989) Neural and developmental ac­tions of lithium: a unifying hypothesis. Cell 59: 411--419

Literatur 391

31. Berridge MJ, Irvine RF (1989) Inositol phosphates and cell signaling. Nature 341: 197-205

32. Bickel MH (1980) Metabolism of antidepressants. In: Hoffmeister F, Stille G (eds) Psychotropic agents, part 1: Antipsychotics and antidepressants. Springer, Berlin Heidelberg New York, pp 551-572

33. Blachly PH (1966) Management of the opiate abstinence syndrome. Am J Psychiatry 122: 742-744

34. Blumer 0, Heilbronn M (1982) Chronic pain as a variant of depressive dis­ease. The pain-prone disorder. J Nerv Ment Dis 170: 381-406

35. Bowery NG, Price GW, Hudson AL, Hill DR, Wilkin GP, Turnbull MJ (1984) GABA receptor multiplicity. Visualization of different receptor types in the mammalian CNS. Neuropharmacology 23: 219-231

36. Brandon S, Cowley P, McDonald C, Neville P, Palmer R, Wellstood-Eason S (1985) Leicester ECT trial: Results in schizophrenia. Br J Psychiatry 146: 177-183

37. Breyer-Pfaff U (1980) Metabolism and kinetics. In: Hoffmeister F, Stille G (eds) Psychotropic agents, part I: Antipsychotics and antidepressants. Springer, Berlin Heidelberg New York, pp 287-304

38. Breyer-Pfaff U, Brinkschulte M, Rein W, Schied HW, Straube E (1983) Pre­diction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data. Pharmacopsychiatria 16: 160-165

39. Brown GW, Birley JLT, Wing JK (1972) Influence of family life on the course of schizophrenic disorders: A replication. Br J Psychiatry 121: 241-258

40. Buchkremer G, Bents H, Horstmann M, Opitz K, Tolle R (1989) Combina­tion of behavioral smoking cessation with transdermal nicotine substitution. Addictive Behaviors 14: 229-267

41. Buller R, Benkert 0 (1990) Panikattacken und PanikstOrung - Diagnose, Validierung und Therapie. Nervenarzt 61: 647-657

42. Bundesminister fiir Jugend, Familie, Frauen und Gesundheit (Hrsg) (1983) Das Arzneimittelgesetz. Bonn

43. Bunney BS (1984) Antipsychotic drug effects of classical and atypical antipsy­chotic drugs on A9 and AlO dopamine neurons. Science 221: 1054-1057

44. Bunney WE, Garland BL (1983) Possible receptor effects of chronic lithium administration. Neuropharmacology 22: 367-372

45. Bunzow JR, van Tol HHM, Grandy OK, Albert P, Salon J, Christie M, Ma­chida CA, Neve KA, Civelli 0 (1988) Cloning and expression of a rat 02 do­pamine receptor cDNA. Nature 336: 783-787

46. Carlsson A, Lindqvist M (1978) Dependence of 5-HT and catecholamine syn­thesis of concentrations of precursor amino acids in rat brain. Naunyn Schmiedebergs Arch Pharmacol303: 157-164

47. Carpenter WT, Hanlon TE, Heinrichs OW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan RW (1990) Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147: 1138-1148

48. Casey DE, Kecpers GA (1988) Neuroleptic side effects: Acute extrapyrami­dal syndromes and tardivc dyskinesia. In: Casey DE, Christensen AV (eds)

392 Literatur

Psychopharmacology: Current Trends. Springer, Berlin Heidelberg New York, pp 74-93

49. Charney DS, Heninger GR, Kleber HD (1986) The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry 143: 831-837

50. Chen J, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990) 8-9-Tetra­hydrocannabinol produces naloxone-blockable enhancement of presynap­tic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacol102: 156-162

51. Chiarello RJ, Cole JO (1987) The use of psychostimulants in general psy­chiatry. Arch Gen Psychiatry 44: 286-295

52. Chiodo LA, Antelman SM (1980) Electroconvulsive shock: Progressive do­pamine autoreceptor subsensitivity independent of repeated treatment. Science 210: 799-801

53. Christison GW, Kirch DG, Wyatt RJ (1991) When symptoms persist: Choos­ing among alternative somatic treatments for schizophrenia. Schizophr Bull 17:217-245

54. Closse A, Frick W, Dravid A, Bolliger G, Hauser D, Sauter A, Tobler H-J (1984) Classification of drugs according to receptor binding profiles. Naunyn Schmiedebergs Arch Pharmacol327: 95-101

55. Cohen SD, Monteiro W, Marks 1M (1984) Two-year follow-up of agora­phobics after exposure and imipramine. Br J Psychiatry 144: 276-281

56. Conte HR, Plutchik R, Wild KY, Karasu TB (1986) Combined psychotherapy and pharmacotherapy for depression. Arch Gen Psychiatry 43: 471-479

57. Coppen A, Bishop ME, Bailey JE, Cattel WR, Price RG (1980) Renal funtion in lithium and non-lithium-treated patients with affective disorders. Acta Psy­chiatr Scand 62: 343-355

58. Corn TH, Thompson C, Checkley SA (1984) Effects of desipramine treatment upon central adrenoceptor function in normal subjects. Br J Psychiatry 145: 139-145

59. Cornu F (1963) Psychopharmakotherapie. In: Gruhle H, Jung R, Mayer­Gross W, Muller M (Hrsg) Psychiatrie der Gegenwart, Bd 112. Springer, Berlin Gbttingen Heidelberg, S 495-659

60. Costa E (1982) Perspectives in the molecular mechanisms of antidepressant action. In: Costa E, Racagni G (eds) Typical and atypical antidepressants. Molecular mechanisms. Raven, New York, pp21-26

61. Creese I (1983) Classical and atypical antipsychotic drugs: New insights. Trends Neurosci 6: 479-481

62. Crow TJ (1980) Molecular pathology of schizophrenia: More than one disease process? Br Med J 280: 66-68

63. Crow TJ (1985) The two-syndrome concept: Origins and current status. Schi­zophr Bull 11: 471-486

64. Crow TJ (1989) A current view of the type II syndrome: Age of onset, intellec­tual impairment, and the meaning of structural changes in the brain. Br J Psy­chiatry 155 (Suppl 7): 15-20

Literatur 393

65. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC (1986) II. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148: 120-127

66. Davidson JD, Pelton S (1986) Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 17: 87-95

67. Davison R, Kaplan K, Fintel D, Parker M, Anderson L, Haring 0 (1988) The effect of clonidine on the cessation of cigarette smoking. Clinical Pharmacol­ogy and Therapeutics 44: 265-267

68. de la Fuente JR (1990) Efficacy of acute treatment in second phase of cross­national collaborative study. J Psychiatric Res 24 (suppI1): 42

69. De Veaugh-Geiss J, Landau P, Katz J (1989) Treatment of obsessive-compul­sive disorder with clomipramine. Psychiatric Annals 19: 97-101

70. De Vry J, Glaser T, Schuurman T, Schreiber R, Traber J (1991) 5-HTIA recep­tors in anxiety. In: Briley M, File SE (eds) New concepts in anxiety. MacMillan Press, London pp 94-129

71. De Vry J, Schreiber R, Horvath E, Traber J (1989) Animal models of 5-HTIA receptor function. Pharmacopsychiatry 22: 194-195

72. Dearry A, Gingrich JA, Falardeau P, Fremeau RT, Bates MD, Caron MG (1990) Molecular cloning and expression of the gene for a human Dl do­pamine receptor. Nature 347: 72-76

73. Delay J, Deniker P (1952) 38 cas de psychoses traites par la cure prolongee et continue de 4568 R. P. Ann Med Psychol110: 364

74. Dessauer M, Gotze U, Tolle R (1986) Periodic sleep deprivation in drug-re­fractory depression. Neuropsychobiology 13: 111-116

75. Devane AF, Dysarz A, Johnson MR, Melvin LS, Howlett C (1988) Determi­nation and characterization of a cannabinoid receptor in the rat brain. Mol Pharmacol34: 605

76. Dilsaver SC, Greden JF (1984) Antidepressant withdrawal phenomena. Bioi Psychiatry 19: 237-256

77. Dorow R, Horowski R, Paschelke G, Amin M, Braestrup C (1983) Severe anxiety induced by FG 7142, a ~-carboline ligand for benzodiazepine recep­tors. Lancet II: 98-99

78. Ehrlich BE, Diamond JM (1980) Lithium, membranes, and manic-depressive illness. J Membr Bioi 52: 187-200

79. Eison MS, Eison AS (1984) Buspiron as a midbrain modulator: anxiolysis unrelated to traditional benzodiazepine mechanisms. Drug Dev Res 4: 109-119

80. Elkin I, Shea T, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilko­nisPA, Leber WR, Docherty JP,FiesterSJ,ParloffMB (1989) National Institute of Mental Health Treatment for Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 46: 971-982

81. Elphick M (1988) The clinical uses and pharmacology of carbamazepine in psychiatry. Internat Clin Psychopharmacol3: 185-203

82. Elphick M (1989) Clinical issues in the use of carbamazepine in psychiatry: a review. Psychol Med 19: 591-604

394 Literatur

83. Emrich HM. Okuma T. Muller AA (eds)(1984) Anticonvulsants in affective disorders. Excerpta Medica. Amsterdam

84. Esparon 1. Kolloori 1, Naylor Gl, McHarg AM, Smith AHW, Hopwood SE (1986) Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br 1 Psychiatry 148: 723-725

85. File SE (1984) Behavioural pharmacology of benzodiazepines. Prog Neuro­psychopharmacol BioI Psychiatry 8: 19-31

86. Fleischhacker Ww. Roth SD. Kane 1M (1990) The pharmacologic treatment of neuroleptic induced akathisia. 1 Clin PsychopharmacollO: 12-21

87. Flygenring 1, Hansen 1, Holst B. Petersen E. Sorensen A (1984) Treatment of alcohol withdrawal symptoms in hospitalized patients. Acta Psychiatr Scand 69: 398-408

8K Fontaine R, Chouinard G (1989) Fluoxetine in the long-term maintenance treatment of obsessive-compulsive disorder. Psychiatric Annals 19: 88-91

89. France RD. Houpt lL. Ellinwood EH (1984) Therapeutic effects of antide­pressants in chronic pain. Gen Hosp Psychiatry 6: 55--63

90. Frank E, Kupfer Dl. Bulik CM, Levenson lA (1990) Imipramine and weight gain during the treatment of recurrent depression. 1 Affective Disord 20: 165-172

91. Frank E. Kupfer Dl. Perel 1M. Comes C. larrett DB. Mallinger AG. Thase ME. McEachran AB. Grochocinski Yl (1990) Three-year outcomes for main­tenance therapies in recurrent depression. Arch Gen Psychiatry 47: 1093-1099

92. Franks P. Harp 1, Bell B (1989) Randomized. controlled trial of clonidine for smoking cessation in a primary care setting. lAMA 262: 3011-3013

93. Franks RD. Dubovsky SL, Lifshitz M, Coen P, Subryan Y. Walker SH (1982) Long-term lithium carbonate therapy causes hyperparathyreoidism. Arch Gen Psychiatry 39: 1074-1077

94. Freyhan FA (1957) Psychomotilitat, extrapyramidale Syndrome und Wir­kungsweisen neuroleptischer Therapien (Chlorpromazin. Reserpin, Prochlor­perazin). Nervenarzt 28: 504--509

95. Friedel RO (1986) The combined use of neuroleptics and ECT in drug-resis­tant schizophrenic patients. Psychopharmacol Bull 22: 928-930

96. Galdi 1. Hirsch S (1983) Discussion about .The causality of depression in schi­zophrenia'. Br 1 Psychiatry 142: 621-625

97. Gardos G, Cole 10 (1983) Tardive dyskinesia and anticholinergic drugs. Am 1 Psychiatry 140: 200-202

98. Gawin FH, Allen D. Humblestone B (1989) Outpatient treatment of .,crack" cocaine smoking with flupenthixol decanoate. Arch Gen Psychiatry 46: 322-325

99. Gawin FH. Kleber HD. Byck R. Rounsaville Bl, Kosten TR, 1 atlow PI, Mor­gan C (1989) Desipramine facilitation of initial cocain abstinence. Arch Uen Psychiatry 46: 117-121

100. Gelenberg Al. Gibson Cl, Wojcik lD (1982) Neurotransmitter precursors for the treatment of depression. Psychopharmacol Bull 18: 7-18

101. Gerken A. Wetzel H. Benkert 0 (1991) Extrapyramidal symptoms and their

Literatur 395

relationship to clinical efficacy under perphenazine treatment. Pharmacopsy­chiatry 24: 132-137

102. Giros B, Sokoloff P, Martres M-P, Riou J-F, Emorine LJ, Schwartz JC (1989) Alternative splicing directs the expression of two D2 dopamine receptor iso­forms. Nature 342: 923-926

103. Gitlin MJ, Weiner H, Fairbanks L, Hershman JM, Friedfeld N (1987) Failure ofT3 to potentiate tricyclic antidepressant response. J Affect Dis 13: 267-272

104. Glassman AH (1984) The newer antidepressant drugs and their cardiovascu­lar effects. Psychopharmacol Bull 20: 272-279

105. Gonzales JP, Brogden RN (1988) Naltrexone. A review of its pharmacody­namic and pharmacokinetic properties and therapeutic efficacy in the man­agement of opioid dependence. Drugs 35: 192-213

106. Goodman WK, Price LH, Delgado PL, Palumbo J, KrystalJH, Nagy LM, Ras­mussen SA, Heninger G R, Charney DS (1990) Specifity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch Gen Psy­chiatry 47: 577-585

107. Goodwin DW, Guzc SB (1989) Psychiatric diagnosis. 4. Aufl., Oxford Univer­sity Press, New York Oxford

108. Goodwin FK, Prange AJ, Post RM, Muscettola G, Lipton MA (1982) Poten­tiation of antidepressant effccts by L-triiodothyronine in tricyclic nonrespon­ders. Am J Psychiatry 139: 34-38

109. Grcenblatt DJ, Abernety DR, Morse DS, Harmatz JS, Shader RI (1984) Clinical importance of the introduction of diazepam and cimetidine. N Eng J Med 310: 1639-1643

110. Greenblatt DJ, Shader RI, Divoll M, Harmatz JS (1984) Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. J Clin Psy­chiatry 45: 192-195

111. Greenblatt DJ, Shader RJ, Franke K, MacLaughlin DS, Harmatz JS. Allen MD, Werner A, Woo E (1979) Pharmacokinetics and bioavailability of in­travenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 68: 57-63

112. Greil W, Schnelle K, Seibold S (1974) Intra/extrazelluUires Lithiumverhaltnis. klinische und experimentelle Untersuchung an Thrombozyten und Ery­throzyten. Arzneimittelforsch 24: 1079-1084

113. Guentert TW (1984) Pharmacokinetics of benzodiazepines and of their meta­bolites. Prog Drug Metab 8: 241-386

114. Gunne L-M, Haggstrom J-E, Sjoquist B (1984) Association with persistent neurolcptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 309: 347-349

115. Haase H-J (1982) Therapie mit Psychopharmaka und anderen seelisches Be­finden beeinflussenden Mcdikamenten. Schattauer, Stuttgart New York

116. Haase J-H (1961) Das therapeutische Achsensyndrom neuroleptischer Medi­kamente und seine Beziehungen zu extrapyramidaler Symptomatik. Fortschr Neurol Psychiatr 29: 245-268

117. Hadcock JR, Malbon CC (1988) Down-regulation of beta-adrenergic recep-

396 Litcratur

tors: Agonist-induced reduction in receptor mRNA levels. Proc Natl Acad Sci USA 85: 5021-5025

118. Haefe\y W (1983) The biological basis of benzodiazepine actions. J Psychoac­tive Drugs 15: 19-39

119. Haefely W (1983) Tranquillizers. In: Grahame-Smith DG, Hippius H, Wino­kur G (cds) Preclinical psychopharmacology. Excerpta Medica, Amsterdam, pp107-151

120. Halmi KA, Eckert E, LaDu TJ, Cohen J (1986) Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry 43: 177-181

121. Helmchen H (1978) Forschungsaufgaben bei psychiatrischer Langzeitmedika­tion. Nervenarzt 49: 534-538

122. Helmchen H (1991) Aufklarung iiber Spathyperkinesen. Nervenarzt 62: 265-268

123. Helmchen H, Hippius H (1969) Pharrnakogene Depression. In: Hippius H, Selbach H (Hrsg) Das depressive Syndrom. Urban & Schwarzenberg, Miin­chen, S 443-446

124. Helmchen H, Miiller-Oerlinghausen B (1981) Die Kombination von Antide­press iva mit anderen Medikamenten. Fortschr Neurol Psychiatr 49: 371-379

125. Heninger GR, Charney DS (1987) Mechanism of action of antidepressant treatments: Implications for the etiology and treatment of depressive disor­ders. In: Meltzer HY (ed) Psychopharmacology. The third generation of pro­gress. Raven, New York

126. Herkenham M, Little MD, Johnson MR, Melvin LS, Howlett AC, Rothman RB, deCosta B, Rice KC (1988) Localization of cannabinoid receptors in brain. Soc Neurosci Abstr 14: 104

127. Hess CW, Scharfetter C, Mumenlhaler M (1984) Klinik der Narkolcpsie-Ka­talcpsie-Syndrome. Nervenarzl 55: 391-40 I

128. Hippius H (1989) The history of c1ozapine. Psychopharmacology 99: S3-S5 129. Hippius H, OberJa K (1986) Das Placebo-Problem. G. Fischer, Stuttgart New

York 130. Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Barton P, Cather R, Cooley

SJ, Ulrich RF, Carter M, Madonia MJ (1988) Dose of t1uphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 45: 797-805

131. Holsboer F, Benkert 0, Meier L Kreuz-Kersling A (1985) Combined es­tradiol and vitamin B6 treatment in women with major depression. Am J Psy­chiatry 142: 658

132. Homykiewicz ° (1978) Biochemische und pathophysiologische Grundlagen des Parkinson-Syndroms. Pharmakotherapie 4: 176-181

133. Horowski R, Dorow R (1982) Die Bedeutung pharmakokinetischer Befunde fiir die klinische Wirkung von Benzodiazepinen. Internist (Berlin) 23: 632-MO

134. Iversen LL (1975) Uptake processes for biogenic amines. In: Iversen LL, Iver­sen SD, Snyder SH (eds) Biochemistry of biogenic amines. Plenum, New York (Handbook of psychopharmacology, vol 3), pp 381-442

Literatur 397

135. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1972) A cholinergic­adrenergic hypothesis of mania and depression. Lancet II: 6732-6735

136. Janssen PAJ (1961) Vergleichende pharmakologische Daten tiber sechs neue basische 4' -Fluorobutyrophen-Derivate. Haloperidol, Haloanison, Triperidol, Methylperidid, Haloperidid und Dipiperon. 1. und 2. Mitteilung. Arzneimit­telforsch 11: 819-824,932-938

137. Jellinek T (1977) Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. Dis Nerv Sys 38: 353-355

138. Jenner P. Mardsen CD (1983) Neuroleptics. In: Grahame-Smith DG, Hippius H, Winokur G (eds) Psychopharmacology 1, part 1: Preclinical psychophar­macology. Excerpta Medica, Amsterdam, pp 180-247

139. Johnson C, Stuckey M, MitchellJ (1983) Psychopharmacological treatment of anorexia nervosa and bulimia. J Nerv Ment Dis 171: 524-534

140. Johnson DAW (1979) Further observations on the duration of depot neuro­leptic maintenance therapy in schizophrenia. Br J Psychiatry 135: 524-530

141. Johnson DAW, Ludlow JM, Street K, Taylor RDW (1987) Double-blind com­parison of half-dose and standard-dose flupenthixol decanoate in the main­tenance treatment of stabilized out-patients with schizophrenia. Br J Psy­chiatry 151: 634-638

142. Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 67: 339-352

143. Johnsson A, Engelmann W (1980) Influence of lithium ions on human circa­dian rhythms. Z Naturforsch 35c: 503-507

144. Joyce PR, Paykel ES (1989) Predictors of drug response. Arch Gen Psychiatry 46:89-99

145. Jus A, Gautier J, Villeneuve A, Jus K, Pires P, Gagnon-Binette M, Fortin C (1978) Pharmacokinetic interaction between amitriptyline and neuroleptics. Neurophysiobiology 4: 305-313

146. Kahn RJ, McNair DM, Lipman RS, Covi L, Rickels K, Downing R, Fisher S, Frankenthaler LM (1986) Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Arch Gen Psychiatry 43: 79--85

147. Kales A (1990) Diagnosis and management of insomnia (letter). N EnglJ Med 323:486

148. Kampf D (1986) Lithium und Nierenfunktion. In: Mtiller-Oerlinghausen B, Greil W (Hrsg) Die Lithiumtherapie. Springer, Berlin Heidelberg New York Tokyo

149. Kane 1M, Honigfeld G, Singer J, Meltzer HY, and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789-796

150. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J (1982) Fluphena­zine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 39: 70-73

151. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-

39H Literatur

Lorenzi 1 (1983) Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 40: R93-R96

152. Kane 1M, Smith 1M (1982) Tardive dyskinesia: Prevalence and risk factors, 1959-1979. Arch Gen Psychiatry 39: 473-4R1

153. Kane 1M. Woerner M. Lieberman 1 (19R5) Tardive dyskinesia: prevalence. in­cidence and risk factors. In: Casey DE. Chase TN, Christensen AV, Gerlach 1 (eds) Dyskinesia - research and treatment. Springer. Berlin Heidelberg New York, pp 72-78

154. Kapfhammer H-P (1990) Umstellungsregime von Kurzzeit- auf Depotneuro­leptika. In: MUller-Oerlinghausen B. Moller H-J. RUther E (Hrsg) Thioxan­thene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York

155. Kapfhammer H-P, RUther E (19R8) Depot-Neuroleptika. Springer, Berlin Heidelberg New York

156. Kaskel D (1977) Intraokularer Druck. Durchblutung. In: Hockwin 0, Koch H-R (Hrsg) Arzneimittelnebenwirkungen am Auge. Fischer, Stuttgart New York, S 145-164

157. Kasper S, Wehr T A, Rosenthal NE (1988) Saisonal abhangige Depressions­formen (SAD). II. Beeinflussung durch Phototherapie und biologische Ergehnisse. N ervenarzt 59: 200-214

158. Katims JJ. Murphy KMM. Snyder SH (1984) Xanthine stimulants and adeno­sine. In: Creese I (cd) Stimulants: Neurochemical. behavioral and clinical per­spectives. Raven, New York. pp63-79

159. Kehabian 1W, Caine DB (1979) Multiple receptors for dopamine. Nature 277: 92-96

160. Keup W (1990) Naltrexon als NUchternheitshilfe bei Opiat-Abhangigkeit. Hcssischcs Arzteblatt 311990: 116-119

161. Kick H (19R I) Fieherzustandc unter Psychopharmakotherapie: Differential­typologie und Diagnostik. Pharmakopsyehiatrie 14: 18-20

162. Kielholz P (1971) Diagnose und Therapie der Depressionen fUr den Praktiker. 3. Auf!. Lehmann, MUnchen

163. Klein DF (1964) Delineation of two drug-responsive anxiety syndromes. Psy­chopharmacology 5: 397-408

164. Klerman GL. Weissman MM. Rounsaville B1, Chcvron ES (1984) Interper­sonal psychotherapy of depression. Basie Books Inc Publishers. New York

165. Klicpera C (1978) Wirkungen und Nebenwirkungen der Stimulantienbehand­lung hei Kindem: Fortschr Neurol Psychiatr 46: 392--414

166. Kline NS (1954) Use of rauwolfia serpentina henth in neuropsychiatric condi­tions. Ann NY Acad Sci 59: 107

167. Kling MA, Manowitz P, Pollack IW (1978) Rat brain and serum lithium con­centrations aftcr acute injections of lithium carbonate and orotatc. 1 Pharm Pharmacol30: 36R-370

168. Knapp S (1983) Lithium. In: Grahama-Smith DG, Cowen P1 (eds) Psycho­pharmacology I. part I: Preclinical psychopharmacology. Excerpta Medica. Amsterdam, pp 71-106

Literatur 399

169. Kniichel M, Ochs HR (1984) Die neuen Benzodiazepine und ihre pharmako­kinetischen Eigenschaften. Med Welt 35: 74-80

170. Kocsis JH, Frances AJ, Voss C, Mann n, Mason BJ, Sweeney J (1988) Imi­pramine treatment for chronic depression. Arch Gen Psychiatry 45: 253-259

171. Konsensus-Papier BGA (1991) Empfehlungen zum Wirksamkeitsnachweis von Nootropika im Indikationsbereich "Demenz" (Phase Ill). Berlin

172. Kosten TR (1990) Current pharmacotherapies for opioid dependence. Psy­chopharmacol Bull 26: 69-74

173. Kracpelin E (1892) Uber die Beeinflussung einfacher Vorgange durch einige Arzneimittel. Fischer, Jena

174. Kramer MC, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Caviccia S, Litle P, Schmidt R, Kimes I (1989) Antidepressants in "depressed" schizophrenic inpatients. Arch Gen Psychiatry 46: 922-928

175. Kuhn R (1957) Uber die Behandlung depressiver Zustande mit einem Imin­odibenzyl-Derivat (G22355). Schweiz Med Wochenschr 87: 1135-1140

176. Kuhs H, Tolle R (1991) Sleep deprivation therapy. Bioi Psychiatry 29: 1129-1148

177. Kupfer DJ, Frank E (1987) Relapse in recurrent unipolar depression. Am J Psychiatry 144: 86-88

178. Kuss HJ, Jungkunz G, Holsboer F (1984) Amitriptyline: Looking through the therapeutic window. Lancet I: 464-465

179. Laakmann G, Schumacher G, Benkert 0, Werder K von (1977) Stimulation of growth hormone secretion by desipramine and chlorimipramine in man. J Clin Endocrinol Metab 44: 1010-1013

180. Laborit H, Huguenard P (1951) L'hibemation artificielle par moyens ph arm a­codynamiques et physiques. Presse Med 59: 1329

180a. Lader M, Petursson H (1983) Abuse liability of anxiolytics. In: Malick JB, Enna SJ, Yamamura HI (eds) Anxiolytics: Neurochemical, behavioral, and clinical perspectives. Raven, New York, pp 201-215

181. Lader M (1985) Ubersicht iiber kIinische Daten von Buspiron in GroBbritan­nien. In: Hippius H (Hrsg) Buspiron-Workshop 1984. Edition Materia Medica, Socio-medico Verlag, Grllieifing, pp 82--87

182. Lader M, Olajide D (1987) A comparison of buspirone and placebo in reliev­ing benzodiazepine withdrawal symptoms. J Clin Psychopharmacol7: 11-15

183. Ladewig D (1982) Abusus von Benzodiazepin-Tranquilizern. Med Welt 33: 1306-1309

184. Ladewig D (1990) Naltrexon - eine wirksame Stiitze im psychosozialen Reha­bilitationsprozeB ehemals Opiatabhangiger. Ther Umschau 47: 247-250

185. Langer SZ (1987) Presynaptic regulation of monoaminergic neurons. In: Melt­zer HY (ed) Psychopharmacology: The third generation of progress. Raven Press, New York pp 151-157

186. Langer SZ, Raisman R (1983) Binding of [3H]imipramine and [3H]desi­pramine as biochemical tools for studies in depression. Neuropharmacology 22: 407--413

187. Lapierre YD, Bulmer DR, Oyewumi LK, Mauguin ML, Knott VJ (1983)

400 Literatur

Comparison of chlonnethiazole (heminevrin) and chlordiazepoxide (Iibrium) in the treatment of acute alcohol withdrawal. Neuropsychobiology 10: 127-130

188. Lavori PW, Keller MB, Klerman GL (1984) Relapse in affective disorders: A reanalysis of the literature using life table methods. J Psychiatr Res 18: 13-25

189. Leff J, Kuipers L, Berkowitz R, Sturgeon D (1985) A controlled trial of social intervention in the families of schizophrenic patients: Two year follow-up. Br J Psychiatry 146: 594--600

190. Leff SE, Creese I (1983) Dopamine receptors re-explained. Trends Pharmacol Sci 4: 463-467

191. Lefkowitz RJ, Caron MG (1988) Adrenergic receptors. Models for the study of receptors coupled to guanine nucleotide regulatory proteins. J Bioi Chern 263:4993-4996

192. Lehmann E, Klieser E, Klimke A, Krach H, Spatz R (1989) The efficacy of ca­vain in patients suffering from anxiety. Pharmacopsychiatry 22: 1-5

193. Leonard BE (1984) Inter-relationship between neurotransmitters. Neuro­pharmacology 23: 213-218

194. Leuner H (1962) Die experimentelle Psychose. Springer, Berlin Heidelberg New York (Monographien aus dem Gesamtgebiet der Neurologie und Psy­chiatry, Bd 95)

195. Levenson JL (1985) Neuroleptic malignant syndrome. Am J Psychiatry 142: 1137-1145

196. Levinson DF, Simpson GM (1986) Neuroleptic-induced extrapyramidal symp­toms with fever. Arch Gen Psychiatry 43: 839-848

197. Libennan RP, Mueser KT, Wallace CJ (1986) Social skills training for schizo­phrenic individuals at risk for relapse. Am J Psychiatry 143: 523-526

198. Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane JM (1989) Clozapine Ef­fects on Tardive Dyskinesia. Psychopharmacol Bull 25: 57--62

199. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, Hollander E, Papp L, Goetz D (1988) Phannacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 49: 252-257

200. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin J, Tricamo E, Markowitz JS, Klein DF (1984) Phenelzine vs. imipramine in atypical depression. Arch Gen Psychiatry 41: 669--677

201. Lippert H (1959) Einfiihrung in die Pharmakopsychologie. Huber, Bern Stutt­gart

202. Lohse MJ, Lenschow V, Schwabe U (1984) Interaction of barbiturates with adenosine receptors in rat brain. Naunyn Schmiedebergs Arch Pharmacol 326:69-74

203. Loomer HP, Saunders IC, Kline NS (1957) A clinical and phannacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Publ Am Psy­chiatr Assoc 8: 129

204. Luchins DJ (1984) Carbamazepine in violent nonepileptic schizophrenics. Psychopharmacol Bull 20: 569--571

Literatur 401

205. Liiddens H, Killisch I, Seeburg PH (1991) More than one alpha variant may exist in a GABAA/benzodiazepine receptor complex. J Recept Res 11: 535-551

206. Liiddens H, Pritchett DB, Kohler M, Killisch I, Keinaenen K, Monyer H, Sprengel R, Seeburg PH (1990) Cerebellar GABAA receptor selective for a behavioural alcohol antagonist. Nature 346: 648"'{)51

207. Lupulover R, Amrein R (1984) Review of clinical investigations with the ben­zodiazepine antagonist Ro 15-1788. Clin Neuropharmacol [Suppll] 7: 668--669

208. Macmillan JF, Crow TJ, Johnson AL, Johnstone EC (1986) The Northwick Park Study of first episodes of schizophrenia. III. Short term outcome in trial entrants and trial eligible patients. Br J Psychiatry 148: 128--133

209. Maier W, Benkert 0 (1987) Methodenkritik des Wirksamkeitsnachweises antidepressiver Therapie. Nervenarzt 58: 595"'{)02

210. Maier W, Roth M, Buller R, Argyle M, Rosenberg R, Brandon S, Benkert 0 (1991) Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity? Psychiatric Annals 21: 374-381

211. Malcolm R, Balenger JC, Sturgis ET, Anton R (1989) Double-blind control­led trial comparing carbamazepine to oxazepam treatment of alcohol withdra­wal. Am J Psychiatry 146: 617"'{)21

212. Manji HK, Hsiao JK, Risby ED, Oliver J, Rudorfer MV, Potter WZ (1991) The mechanisms of action of lithium. I. Effects on serotonergic and nora­drenergic systems in normal subjects. Arch Gen Psychiatry 48: 505-512

213. Marder SR, Putt en T van, Mintz J, Lebell M, McKenzie J, May PRA (1987) Low- and conventional-dose maintenance therapy with fluphenazine deca­noate. Two-year outcome. Arch Gen Psychiatry 44: 518-521

214. Marder SR, Putten T van, Mintz J, McKenzie J, Lebell M, Faltico G, May PRA (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psy­chiatry 41: 1025-1029

215. Margraf J, Schneider S (1990) Panik. Angstanfalie und ihre Behandlung. 2. Aufl. Springer, Berlin Heidelberg New York

215 a. Marks J (1983) The benzodiazepines - for good or evil. Neuropsychobiology 10: 115-126

216. Marks 1M, Gray S, Cohnen D, Hill R, Mawson D, Ramm E, Stern RS (1983) Imipramine and brief therapist-aided exposure in agoraphobics having self­exposure homework. Arch Gen Psychiatry 40: 153-162

217. Mavissakalian M, Michelson L, Dealy RS (1983) Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. Br J Psychiatry 143: 348-355

218. McGrath SD (1975) A controlled trial of chlormethiazole and chlordiazepox­ide in the treatment of the acute withdrawal phase of alcoholism. Br J Addict 70:81-90

219. McMillen BA (1983) CNS stimulants: two distinct mechanisms of action for amphetamine-like drugs. Trends Pharmacol Sci 4: 429-432

220. Meier-Ewert K (1967) Thromboembolische Komplikationen bei neuro- und thymolcptischer Behandlung. Deutsche Med Wochenschr 92: 2174--2178

402 Literatur

221. Mellerup ET, Plenge P (1990) The side effects of lithium. Bioi Psychiatry 28: 464-466

222. Meltzer HY (1989) Duration of a clozapine trial in treatment resistant schizo­phrenia. Arch Gen Psychiatry 46: 672

223. Melzacka M, Danek L (1983) Pharmacokinetics of amitriptyline-N-oxide in rats after single and prolonged oral administration. Pharmacopsychiat 16: 30-34

224. Mense S (1983) Basic neurobiologic mechanisms of pain and analgesia. Am 1 Med 75 (5A): 4-14

225. Miller NS, Gold MS, Millman RB (1989) Cocaine: General characteristics, abuse, and addiction. NY State 1 Med 89: 390-395

226. Mohler H, Okada T (1977) Benzodiazepine receptor: Demonstration in the central nervous system. Science 198: 849-851

227. Moller Hl, Kissling W, Lang C, Doerr P, Pirke KM, Zerssen D von (1982) Ef­ficacy and side effects of haloperidol in psychotic patients: Oral versus in­travenous administration. Am 1 Psychiatry 139: 1571-1575

228. Monsma Fl, McVittie LD, Gerfen CR, Mahan LC (1989) Multiple Dz do­pamine receptors produced by alternative RNA splicing. Nature 342: 926-929

229. Mukherjee S, Rosen AM, Caracci G, Shukla S (1986) Persistent tardive dys­kinesia in bipolar patients. Arch Gen Psychiatry 43: 342-346

230. Miiller-Oerlinghausen B (1980) Clinical pharmacology (pharmacokinetics). In: Hoffmeister F, Stille G (eds) Psychotropic agents, part I: Antipsychotics and antidepressants. Springer, Berlin Heidelberg New York, pp 267-285

231. Miiller-Oerlinghausen B, Greil W (Hrsg)(1986) Die Lithiumtherapie. Springer, Berlin Heidelberg New York Tokyo

232. Murphy lK, Edwards NB, Downs AD, Ackerman Bl, Rosenthal TL (1990) Effects of doxepin on withdrawal symptoms in smoking cessation. Am 1 Psy­chiatry 147: 1353-1357

233. Naylor Gl, Scott C (1980) Depot injections for affective disorders. Br 1 Psy­chiatry 136: 105

234. Nishizuka Y (1984) Turnover of inositol phospholipids and signal transduc­tion. Science 225: 1365-1370

235. Nolen WA, van de Putte 11, Dijken WA, KamplS, BiansjaarBA, KramerHl, Haffmans 1 (1988) Treatment strategy in depression. 1. Non-tricyclic and se­lective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 78: 668-675

236. Nolen WA, van de Putte 11, Dijken WA, Kamp lS, Blansjaar BA, Kramer Hl, Haffmans 1 (1988) Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 78: 676-{)83

237. Ochs HR (1983) Benzodiazepine: Bedeutung der Kinetik flir die Therapie. Klin Wochenschr 61: 213-224

238. Ochs HR, Greenblatt Dl, Verburg-Ochs B, Locniskar BS (1984) Comparative

Literatur 403

single-dose kinetics of oxazolam, prazepam, and clorazepate: Three precur­sors of desmethyldiazepam. J Clin Pharmacol24: 446-451

239. Ochs HR, Steinhaus E, Locniskar A, Kniichel M, Greenblatt DJ (1982) Des­methyldiazepam kinetics after intravenous, intramuscular, and oral adminis­tration of clorazepate dipotassium. Klin Wochenschr 60: 411-415

240. O'Dowd BF, Lefkowitz RJ, Caron MG (1989) Structure ofthe adrenergic and related receptors. Ann Rev Neurosci 12: 67--83

241. Okuma T, Yamashita I, Takahashi R, Itoh H, Kurihara M, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K (1989) Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders. Pharmacopsychiat 22: 47-53

242. Olajide D, Lader M (1987) A comparison of bus pirone, diazepam, and placebo in patients with chronic anxiety states. J Clin Psychopharmacol 7: 148--152

243. Olpe HR, Schellenberg A (1980) Reduced sensitivity of neurons to noradre­naline after chronic administration of desipramine. Eur J Pharmacol 74: 195-206

244. Oppenheim G (1982) Drug-induced rapid cycling: Possible outcomes and management. Am J Psychiatry 139: 939-941

245. Oswald I (1984) Hypnotic drugs for 1984. In: Hindmarch I, Ott H, Roth (eds) Sleep, benzodiazepines, and performance. Psychopharmacology Supple men­tum 1. Springer, Berlin Heidelberg, New York Tokyo, pp. 85-90

246. Overall JE (1978) Prior psychiatric treatment and the development of breast cancer. Arch Gen Psychiatry 35: 898--899

247. Owen RT, Tyrer P (1983) Benzodiazepine dependence. A review of the evi­dence. Drugs 25: 385-398

248. Owens DGC, Johnstone EC, Crow TJ, Frith CD, Jagoe JR, Kreel L (1985) Lateral ventrical size in schizophrenia: Relationship to the disease process and its clinical manifestations. Psycholog Med 15: 27-41

249. Palsson A (1986) The efficacy of early chlormethiazole medication in the prevention of delirium tremens. A retrospective study of the outcome of dif­ferent drug treatment strategies at the Helsingborg psychiatric clinics, 1975-1980. Acta Psychiatr Scand 73 (SuppI329): 14~145

250. Parker G, Johnston P, Hayward L (1988) Parental ,Expressed Emotion' as a predictor of schizophrenic relapse. Arch Gen Psychiatry 45: 806--813

251. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL (1988) Return of symp­toms after discontinuation of clomipramine in patients with obsessive-com­pUlsive disorder. Am J Psychiatry 145: 1521-1525

252. Pellow S, File SE (1984) Multiple sites of action for anxiogenic drugs: Beha­vioural, electrophysiological and biochemical correlations. Psychopharmaco­logy (Berlin) 83: 304-315

253. Pepin MC, Beaulieu S, Barden S (1989) Antidepressants regulate glucocorti­coid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 6: 77--83

254. Peroutka SJ (1987) Serotonin receptors. In: Meltzer HY (ed) Psychopharma­cology: The third generation of progress. Raven Press, New York pp 303-311

404 Literatur

255. Peroutka Sl, Snyder SH (1980) Relationship of neuroleptic drug cffects at brain dopamine, serotonin, a-adrenergic and histamine receptors to clinical potency. Am 1 Psychiatry 137: 1518-1522

256. Perry Pl, Miller DD, Arndt Sv, Cadoret Rl (1991) Clozapine and norclo­zapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am 1 Psychiatry 148: 231-235

257. Petty F, Sherman AD (1983) Animal models of psychiatric illness: Pharmaco­logical aspects. In: Hippius H, Winokur G (eds) Psychopharmacology 1, part 2: Clinical Psychopharmacology. Excerpta Medica, Amsterdam, pp 444-459

258. Philipp M, Fickinger M (1992) Psychotropic drugs in the management of chronic pain syndromes. Pharmacopsychiatry (im Druck)

259. Pietzcker A, Gaebel W, Kiipcke W, Linden M, Muller P, Muller-Spahn F, Schussler G, Tegeler J (1986) A german multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Pharmacopsychiatry 19: 161-166

260. Pietzker A (1988) Das maligne neuroleptische Syndrom. Nervenarzt 59: 691-700

261. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill lL, Tolliver Tl, Murphy DL (1990) Controlled comparisons of clomipramine and f!uoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 47: 926-932

262. Plenge P, Mellerup ET, Bolwig TG, Brun C, Hetmar 0, Ladefoged J, Larsen S, Rafaelsen 01 (1982) Lithium treatment: Does the kidney prefer one daily dose instead of two? Acta Psychiat Scand 66: 121-128

263. Pletscher A, Gey KF, Zeller P (1960) Monoaminoxydase-Hemmer, Chemie, Biochemie, Pharmakologie, Klinik. Fortschr Arzneimittelforsch 2: 417-590

264. Piildinger W, Wider F (1990) Index Psychopharmacorum, 7. Auf!. Hans Huber, Bern Stuttgart Toronto

265. Pope HG, Aizley HG, Keck PE, McElroy SL (1991) Neuroleptic malignant syndrome: long-term follow-up of 20 cases. 1 Clin Psychiatry 52: 208-212

266. Pope HG jr, Hudson JI (1986) Antidepressant drug therapy for bulimia: cur­rent status. 1 Clin Psychiatry 47: 339-345

267. Post RM (1982) Use of the anticonvulsant carbamazepine in primary and sec­ondary affective illness: Clinical and theoretical implications. Psychol Med 12: 701-704

268. Post RM (1987) Mechanisms of action of earbamazepine and related anticon­vulsants in affective illness. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp 567-576

269. Post RM (1988) Time eourse of clinical effects of carbamazepine: implications for mechanisms of action. 1 Clin Psychiatry 49 (SuppI4): 35-46

270. Post RM, Kramlinger KG, Altshuler LL, Ketter T, Denicoff K (1990) Treat­ment of rapid cycling bipolar illness. Psychopharmacol Bull 26: 37-47

271. Prescott LF (1983) Safety ofthe benzodiazepines. In: Costa E (ed) The benzo­diazepines: From molecular biology to clinical practice. Raven, New York, pp 253-265

272. Preskorn SH, Dorey RC, lerkovich GS (1988) Therapeutic monitoring of tri­cyclic antidepressants. Clin Chern 34(5): 822-828

Literatur 405

273. Prien RF, Gelenberg AJ (1989) Alternatives to lithium for preventive treat­ment of bipolar disorder. Am J Psychiatry 146: 840-848

274. Prien RF, Kupfer DJ (1986) Continuation drug therapy for major depressive episodes: How long should it be maintained? Am J Psychiatry 143: 18-23

275. Prien RF, Kupfer DJ, Masky PA, Small JG, Tuason VB, Voss CB, Johnson WE (1984) Drug therapy in the prevention of recurrences in unipolar and bi­polar affective disorders. Arch Gen Psychiatry 41: 1096~11O4

276. Pritchett DB, Sontheimer H, Shivers BD, Ymer S, Kettenmann H, Schofield PR, Seeburg PH (1989) Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature 338: 582~585

277. Puia G, Vicini S, Seeburg PH, Costa E (1991) Influence of recombinant gamma-aminobutyric acid-A receptor subunit composition on the action of allosteric modulators of gamma-aminobutyric acid-gated Cl' currents. Mol PharmacoI39:691-696

278. Putten T van, May PRA (1978) ,Akinetic depression' in schizophrenia. Arch Gen Psychiatry 35: 1101~1107

279. Quitkin FM (1985) The importance of dosage in prescribing antidepressants. Br J Psychiatry 147: 593~597

280. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Rabkin J, Tricamo E, Wagner S, Ocepek-Welikson K, Nunes E, Rabkin JG, Klein DF (1990) A typi­cal depression, panic attacks, and response to imipramine and phenelzine. Arch Gen Psychiatry 47: 935~941

281. Reid WH, Bloubin P, Schermer M (1976) A review of psychotropic medica­tion and the glaucomas. Int Pharmacopsychiatry 11: 163~174

282. Reynolds GP (1983) Increased concentrations and lateral asymmetry of amyg­dala dopamine in schizophrenia. Nature 305: 527~529

283. Riblet LA, Taylor DP, Eison MS, Stanton HC (1982) Pharmacology and neu­rochemistry of bus pirone. J Clin Psychiatry 43: 11~16

284. Richards JG, Mohler H (1984) Benzodiazepine receptors. Neuropharma­cology 23: 233~242

285. Richelson E, Nelson A (1984) Antagonism by antidepressants of neurotrans­mitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230: 94-102

286. Richelson E, Pfennig M (1984) Blockade by antidepressants and related com­pounds of biogenic amine uptake into rat brain synaptosomes: Most antide­pressants selectively block norepinephrine uptake. Eur J Pharmacol104: 277~ 286

287. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H (1988) Long-term treatment of anxiety and risk of withdrawal. Arch Gen Psychiatry 45: 444-450

288. Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M (1991) Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48: 166-170

289. Ritola E, Malinen L (1981) A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psy­chiatr Scand 64: 254-259

406 Literatur

290. Robertson MM, Trimble MR (1982) Major tranquillizers used as antidepress­ants. J Affective Disord 4: 173-193

291. Robinson BJ, Robinson GM, Maling TJB, Johnson RH (1989) Is clonidine useful in the treatment of alcohol withdrawal? Alcohol Clin Exp Res 13: 95-98

292. Roder V, Brenner H-D, Kienzle N, Hodel B (1988) Integriertes Psychologi­sches Therapieprogramm (IPT) fUr schizophrene Patienten. Psychologie Ver­lags Union, Munchen Weinheim

293. Roose SP, Glassman AH, Gairdina EGY, Johnson LL, Walsh BT, Woodring S, Bigger JT Jr. (1986) Nortryptiline in depressed patients with left ventricular impainnent. JAMA 256: 3253-3257

294. Rosebush PI, Stewart TO, Gelenberg AJ (1989) Twenty neuroleptic rechal­lenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 50: 295-298 und 472

295. Roth G (1964) Psychopharmakon. Confin Psychiatr 7: 179-182 296. Roy-Byrne pp, Joffe RT, Uhde TW, Post RM (1984) Approaches to the evalu­

ation and treatment of rapid-cycling affective illness. Br J Psychiatry 145: 543-550

297. Rupniak NMJ, Kilpatrick G, Hall MD, Jenner P, Marsden CD (1984) Dif­ferential alterations in striatal dopamine receptor sensitivity induced by re­peated administration of clinical equivalent doses of halopcridol, sulpiride or clozapine in rats. Psychopharmacology (Berlin) 84: 512-519

298. Salzman C, Baltcr M, Ellinwood E, Gallant OM, Gillin JC, Greenblatt OJ, Griffiths R, Hollister LE, Kleber HD, O'Brien C, Pincus H, Rickels K, Sel­lers E (1990) American Psychiatric Association Task Force on Benzodia­zepine dependency, toxicity, and abuse. American Psychiatric Press, Wash­ington

299. Scheyen JD von, Kammen DP van (1979) Clomipramine-induced mania in unipolar depression. Arch Gen Psychiatry 36: 560-565

300. Schied HW, Braunschweiger M, Schupmann A (1986) Treatment of delirium tremens in Gennan psychiatric hospitals: results of a recent survey. Acta Psy­chiatr Scand 73 (SuppI329): 153-156

301. Schmidt LG, Grohmann R, Muller-Oerlinghausen B, Otto M, Ruther E, Wolf B (1989) Prevalence of benzodiazepine abuse and dependence in psychiatric inpatients with different nosology. Br J Psychiatry 154: 839--843

302. Schmidt S, Greil W (1987) Carbamazepin in der Behandlung psychiatrischer Erkrankungen. Nervenarzt 58: 719-736

303. Schopf J (1989) Lithiumzugabe zu Thymoleptika als Behandlung therapiere­sistenter Depressionen. Nervenarzt 60: 200-205

303 a. Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39: 486-487

304. Schou M (1976) What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 54: 193-197

305. Schou M (1983) Prophylaktische Lithiumbehandlung bei manisch-depressiver

Literatur 407

Krankheit: Erfahrungen und Fortschritte der letzten Jahre. Nervenarzt 54: 331-339

306. Schou M (1984) Long-lasting neurological sequelae after lithium intoxication: Acta Psychiatr Scand 70: 594-602

307. Schou M, Amdisen A, Thomsen K, Vestergaard P, Hetmar 0, Mellerup ET, Plenge P, Rafaelsen OJ (1982) Lithium treatment regimen and renal water handling: The significance of dosage pattern and tablet type examined through comparison of results from two clinics with different treatment regimens. Psychopharmacology 77: 387-390

308. Sellers EM (1984) Ethanol-psychotropic drug interactions: Pharmacokinetics. Psychopharmacol Bull 20: 497-499

309. Shalev A, Munitz H (1986) The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 73: 337-347

310. Shaw GK (1986) Chlormethiazole in the management of alcohol withdrawal. Acta Psychiatr Scand 73 (Suppl329): 162-166

311. Shepherd M, Crow T, Lader MH, Johnson AL (1981) Continuation therapy with lithium and amitriptyline in unipolar depressive illness: A controlled clinical trial. Psychol Med 11: 409-416

312. Shukla S, Cook BL, Miller MG (1985) Lithium-carbamazepine versus lithium­neuroleptic prophylaxis in bipolar illness. J Affect Dis 9: 219-222

313. Simons AD, Murphy GE, Levine JL, Wetzel RD (1986) Cognitive therapy and pharmacotherapy for depression: sustained improvement over one year. Arch Gen Psychiatry 43: 43-48

314. Singh MM, Kay SR (1979) Therapeutic antagonism between anticholinergic antiparkinsonism agents and neuroleptics in schizophrenia. Neuropsychobiol­ogy 5: 74

315. Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E (1988) Postpsy­chotic depression and negative symptoms: An investigation of syndromal overlap. Am J Psychiatry 145: 1532-1537

316. Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB (1987) Adjunctive imipramine in the treatment of postpsychotic depression: A controlled trial. Arch Gen Psychiatry 44: 533-539

317. Skolnick P, Paul SM (1982) Benzodiazepine receptors in the central nervous system. Int Rev Neurobiol23: 103-140

318. Smith DE, Wesson DR (1983) Benzodiazepine dependency syndromes. J Psy­choactive Drugs 15: 85-95

319. Smith DF (1976) Lithium orotate, carbonate and chloride: Pharmacokinetics, polydipsia and polyuria in rats. Br J Pharmacol56: 399-402

320. Snyder SH (1982) Schizophrenia. Lancet II: 970--974 321. Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz lC (1990) Mole­

cular cloning and characterization of a novel dopamine receptor (D3) as a tar­get for neuroleptics. Nature 347: 146-151

322. Soldatos CR, Kales A, Cadieux RJ (1983) Treatment of sleep disorders II: Narcolepsy. Ration Drug Ther 17: 1-7

323. Spiker DG, Cofsky-Weiss J, Dealy RS, Griffin SJ, Hanin I, Neil JF, Perel 1M,

408 Literatur

Rossi AJ, Soloff PH (1985) The pharmacological treatmcnt of delusional de­pression. Am J Psychiatry 142: 430-436

324. Squires RF, Braestrup RF (1977) Benzodiazepine receptors in rat brain. Na­ture 266: 732-734

325. Stille G (1%8) Pharmacological investigations of antidepressant compounds. Pharmakopsychiatr Neuro-Psychopharmacol1, 2: 92-106

326. Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuro­leptica (anhand von pharmakologischen und klinischen Befunden mit Clo­zapin). Pharmakopsychiatr Neuropsychopharmacol4: 182-191

327. Stoof JC, Kebabian JW (1984) Two dopamine receptors: Biochemistry, physi­ology and pharmacology. Life Sci 35: 2281-2296

328. Sulser F (1984) Regulation and function of noradrenaline receptor systems in brain. Psychopharmacological aspects. Neuropharmacology 23: 255-261

329. Sunahara RK, Guan H-C, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, van Tol HHM, Niznik HB (1991) Cloning of the gene for a human dopamine Ds receptor with higher affinity for dopamine than D!. Na­ture 350: 614--619

330. Sunahara RK, Niznik HB, Weiner DW, Stormann TM, Brann MR, Kennedy JL, Gelernter JE, Rozmahel R, Yang Y, Israel Y, Seeman P, O'Dowd B (1990) Human dopamine D! receptor encoded by an intronless gene on chromosome 5. Nature 347: 80-83

331. Suranyi-Cadotte BE, Bodnoff SR, Weiner SA (1990) Antidepressant-anxio­lytic interactions: Involvement of the benzodiazepine-GABA and serotonin systems. Prog Neuro-Psychopharmacol Bioi Psychiat 14: 633--654

332. Task Force on the Use of Labatory Tests in Psychiatry (1985) Tricyclic antide­pressants - Blood level measurements and clinical outcome: An APA Task Force report. Am J Psychiatry 142: 155-162

333. Taylor PJ, Fleminger JJ (1980) ECT for schizophrenia. Lancet I: 1380-1382 334. Tegeler J, Lehmann E, Weiher A, Heinrich K (1990) Safety of long-term

neuroleptanxiolysis with fluspirilene 1.5 mg per week. Pharmaeopsychiatry 23:259-264

335. Teich MJ, Agras WS, Taylor WB. Roth WT, Gallen CC (1985) Combined pharmacological and behavioral treatment of agoraphobia. Behav Res Ther 23: 325-335

336. Thompson JW jf., Ware MR, Blashfield RK (1990) Psychotropic medication and priapism: A comprehensive review. J Clin Psychiatry 51: 430-433

336a. Tyrer P, Rutherford D, Huggett T (1981) Benzodiazepine withdrawal symp­toms and propanolol. Lancet I: 520-522

337. Uhl GR, Kuhar MJ (1984) Chronic neuroleptic treatment enhances neuro­tensin receptor binding in human and rat substantia nigra. Nature 309: 350-352

338. Uhlenhuth EH, DeWitt H, Balter MB, Johanson LE, Mellinger GD (1988) Risks and benefits of long-term benzodiazepine use. J Clin Psychopharmacol 8:161-167

339. Ungvari G (1982) Neuroleptische Behandlung und unerwarteter Tod. Fort­schr Neurol Psychiatr 50: 267-273

Literatur 409

340. Vallar L, Meldolesi J (1989) Mechanisms of signal transduction at the do­pamine Dz receptor. Trends Pharmacol Sci 10: 74-77

341. van der Kroef C (1979) Reactions to triazolam. Lancet II: 526 342. van Praag HM (1978) Amine hypotheses of affective disorders. In: Iversen LL,

Iversen SD, Snyder SH (eds) Biology of mood and antianxiety drugs. Plenum, New York (Handbook of psychopharmacology, vol 13), pp 187-297

343. van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N (1991) Neuro­leptic plasma levels. Schizophr Bull 17: 197-216

344. van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli 0 (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic c1ozapine. Nature 350: 610--614

345. Vardy MM, Kay SR (1983) LSD psychosis or LSD-induced schizophrenia? Arch Gen Psychiatry 40: 877-883

346. Verdoom TA, Draguhn A, Ymer S, Sceburg PH, Sakmann B (1990) Func­tional properties of recombinant rat GABAA receptors depend upon subunit composition. Neuron 4: 919-928

347. Vogel GW (1983) Evidence of REM sleep deprivation as the mechanism of action of antidepressant drugs. Prog Neuropsychopharmacol Bioi Psychiatry 7:343-349

348. Vollmer K-O (1981) Zur pharmakokinetischen Differenzierung von Benzo­diazepinen. Fortschr Med 99: 829---834

349. Waddington JL, Youssef HA, Dolphin C, Kinsella A (1987) Cognitive dys­function, negative symptoms and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criteria of their abnormality. Arch Gen Psychiatry 44: 901-912

350. Waller DG (1989) Lithium and the kidney: an update. Psychol Med 19: 825---831 351. Walsh BT, Gladis M, Roose SR, Stewart JW, Stetner F, Glassman AH (1988)

Phenelzine vs. placebo in 50 patients with bulimia. Arch Gen Psychiatry 45: 471-475

352. Walsh TD (1983) Antidepressants in chronic pain. Clin Neuropharmacol 6: 271-295

353. Walther-Buel H (1953) Uber Pharmakopsychiatrie. Schweiz Med Wochenschr 83:483-487

354. Wehr TA, Goodwin FK (1979) Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 36: 555-559

355. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW (1988) Rapid cycling affec­tive disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 145: 179-184

356. Wehr TA, Wirz-Justice A (1982) Circadian rhythm mechanisms in affective ill­ness and in antidepressant drug action. Pharmacopsychiatria 15: 31-39

357. Weiner WJ, Goetz CG, Nausieda PA (1978) Respiratory dyskinesias: Extrapy­ramidal dysfunction and dyspnea. Ann Int Med 88: 327-331

358. Weinstein MR (1980) Lithium treatment of women during pregnancy and in the post-delivery period. In: Johnson FN (ed) Handbook of lithium therapy. MTP Press, Lancaster

410 Litcratur

359. Wetzel H. Benkert 0 (1993) Dopamine autorcccptor agonists in the treatment of schizophrenic disorders. Mod Prog Neuro-Psychopharmacol Bioi Psy­chiatry I() (im Druck)

360. Wetzel H, Heuser I, Benkert 0 (1988) Benzodiazepines for catatonic symp­toms, stupor and mutism. Pharmacopsychiatry 21: 394-395

3()1. Wilhelm M (1972) Die Chemie polyzyklischer Psychopharmaka. Serendipity oder Systematik? In: Kielholz P (Hrsg) Depressive Zustande. Huber, Bern Stuttgart Wien

3()2. Willner P (1984) The validity of animal models of depression. Psychopharma­cology Berlin 83: 1-16

363. Wolkin A. Barouche F, Wolf AP, Rotrosen J. Fowler JS, Shiue C-Y, Cooper TB, Brodie JB (1989) Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146: 905-908

3M. Wolkin A. Brodie JD. Barouche JE Rotrosen J. Wolf AP. Smith M, Fowler J. Cooper TB (1989) Dopamine receptor occupancy and plasma haloperidolle­vels. Arch Gen Psychiatry 46: 482--483

3()5. Wood AJ, Goodwin GM (1987) A review of the biochemical and neurophar­macological actions of lithium. Psychol Med 17: 579-600

3()6. Yadalam KG. Simpson GM (1988) Changing from oral to depot fluphenazine. J Clin Psychiatry 49: 346-348

3()7. Youdim MBH. Finberg JPM (1983) Monoamine oxidase inhibitor antide­pressants. In: Grahame-Smith DG. Cowen PJ (eds) Psychopharmacology 1, part I: Preclinical psychopharmacology. Excerpta Medica, Amsterdam, pp 38-70

3()8. Youdim MBH, Finberg JPM (1991) New directions in monoaminoxidase A and B. Selective inhibitors and substrates. Biochcm Pharmacol41: 155-162

369. Zhou Q-Y. Grandy DK. Thambi L. Kushner JA, van Tol HHM, Cone R. Prib­now D. Salon J. Bunzow JR, Civelli 0 (1990) Cloning and expression of human and rat DI dopamine receptors. Nature 347: 76-80

Abkiirzungsverzeichnis

ACh Azetylcholin 5-HTP 5-Hydroxytroptophan ADH Antidiuretisches Hormon, HVS Homovanillinsaure

Vasopressin ICD International Classificatim AMG Arzneimittelgesetz of Diseases APA American Psychiatric Asso- LSD Lysergsaurediathylamid

ciation MAOH Monoaminoxidasehemmer ATP Adenosintriphosphat MHPG 3-Methoxy-4-hydroxy-cAMP Zyklisches Adenosin-3',5'- phenylglykol

Monophosphat MR Magnetic Resonance CK Kreatinkinase MSH Melanozytenstimulierende, COMT Katecholamin-O-Methyl- Hormon

transferase NA Noradrenalin DA Dopamin NMDA N-Methyl-D-aspartat DDAVP Desamino-0-Argininvaso- 8-0H- 8-Hydroxydiaminopropyl-

pressin DPAT tetra lin DNA Desoxyribonukleinsaure PET Positronen-Emissions-L-DOPA 3,4-Dihydroxyphenylalanin Tomographie DOPAG 3,4-Dihydroxyphenyl-Essig- REM Rapid Eye Movements

saure SPECT Single Photon Emission DSM- Diagnostic and Statistical Computerized Tomography III-R Manual of Mental Disor- T3 Trijodthyromin

ders, Third Edition, Revised T4 L-Thyroxin, Tetrajodthyro-99mTc_ Technetium-99m-Diethylen- min DTPA triaminpentaacetat THC 0-9-Tetrahydrocannabinol EKE Elektrokrampfbehandlung TRH Thyreotropin Releasing GABA Gammaaminobuttersaure Hormone GFR glomerulare Filtrationsrate TSH Thyreoidea-stimulierendes GTP Guanosyltriphosphat Hormon, Thyreotropin 5-HIES 5-Hydroxyindolessigsaure TZA Trizyklische Antidepressiva 5-HT Serotonin (5-Hydroxy- WHO World Health Organiza-

tryptamin) tion

Sachverzeichnis

Abhiingigkeit 346ff. - Benzodiazepine 259ff. Adenylatzyklase, Wirkung von Li-

thium 106, 107 ADH (Antidiuretisches Hormon,

Vasopressin) 107 affektive Psychosen - bipolare 110,111 - Medikamente zur Phasenprophy-

laxe 100ff. Age Associated Memory Impair­

ment 331 Agranulozytose 173ff. Akathisie, Behandlung mit Proprano­

lol 159 akinetische Depression 170 Akutsituationen, psychiatrische, Phar-

makotherapie 377ff. Aldehydderivate 323 ff. Alkohol 348ff. - Alkoholderivate 323ff. - Alkoholentzug - - Carbamazepin 349 - - Clonidin 350 - - Entzugssyndrome 348 ff. - Alkoholhalluzinose 350 - alkoholischer Eifersuchtswahn 350 - Alkoholkrankheit 351 - Intoxikation 348 a-Adrenozeptoren, SUbtypen 22 Amantadin 38 Amine, biogene 14 Aminpriikursoren, Wirkungsprinzip

26

Amphetamin 357f.,375 Angehorigenarbeit, Schizophrenie

183 Angiotensin-converting-enzyme-Hem­

mer 119 Angstsyndrom, generalisiertes

76 - Benzodiazepintherapie 254 Anorexia nervosa 37 Antibiotika 119 Anticholinergika, Phrophylaxe mit

182 Antidepressiva 8ff., 20, 294ff., 324,

369 - Akutwirkungen 18 - allergische Reaktionen 48 - anticholinerge Wirkung 49, 50 - antriebssteigernde Wirkung 32 - Auslosung manischer Phasen 49,

58 - Blutbildkontrollen 51 - Blutzellschiidigung 51 - dopaminerges System 24 - Dosisverteilung 57 - endokrine Wirkungen 48 - Erhaltungsdosis 56 - Erhaltungstherapie 58 - Fahrtauglichkeit 52 - Gewichtszunahme 48 - Indikationen 29 - Indikationsspektrum 10, 38 - Kombinationen - - mit Benzodiazepinen 49 - - mit Neuroleptika 55

414

Antidepressiva - - mit Psychotherapie 42 - Komplikationen 48 - Krampfanfiille 48 - neuroendokrinologische Unter-

suchungen 25 - nichttrizyklische 10,31,32 - orthostatische Hypotonie 46 - Pharmakologie 11 - Phasenprophylaxe 129 - Routineuntersuchungen (tabellari-

sche Ubersicht) 51 - Riickfallprophylaxe 58 - bei Schlafstorungen 57 - Schwangerschaft 50 - sedierende Wirkung 30, 32 - serotonerges System 24 - Standarddosierung 59 - Suppression des REM-Schlafs 26 - Symptomprovokation bei Schizo-

phrenie 32 - trizyklische 31,61 - Uberdosierung 49 - Uberleitungsst6rungen 46 - vegetative Nebenwirkungen 45ff. - Vergiftungen mit 49 - Wirkungslatenz 13 - Wechselwirkungen mit Lithium 55 - Wirkungslatenz 21,56 - Wirksamkeitsnachweis 10 - Wirkungen - - anxiolytische 20 - - chronische 21 - - aufNeurotransmitter-Rezepto-

ren 20 - - sedierende 20 - Wirkungsspektrum 29 - Zielsymptome (oder Zielsyndro-

me) 29 Antidiuretisches Hormon (ADH),

Vasopressin 107 Antihistaminika 324 Antiparkinsonmittel 373 ff. Arzneimittelexantheme, unter Neuro-

leptika 167

Sachverzeichnis

Aversionsbehandlung 351 Azapirone 290 Azetylcholinhypothese - M. Alzheimer 332 - Depression 14

Barbiturate 325 Benzamide 232 Benzodiazepine - Abhangigkeit 259ff. - antidepressive Wirkung 40 - Behandlungsdauer 39,264 - chronische Einnahme 259 - bei Depression 32, 39 - Dosiseinstellung 264 - Einteilung nach Halbwertszeiten

251 ff. - Entgiftung 262 - Entzugssymptome 261 - bei generalisierter Angstst6rung

35,254 - Indikationen 253 - in Kombinationspraparaten 40 - Kombination mit Antidepressiva

49 - Kontraindikationen 263 - Non-Benzodiazepine, Hypnotika

305 - bei Panikstorung 33,253 - Pharmakokinetik 248ff. - Rezeptoren 242ff. - Rezeptorstruktur 245 - Schizophrenie 186 - Schwangerschaft 259 - Stillzeit 259 - Strukturchemie 238 - bei Suizidalitat 39, 254 - Oberdosierung 258 Benzodiazepinhypnotika 301,306 p-Adrenozeptoren, SUbtypen 22 p-Carbolin-3-carboxylatmethylamid

246 p-Down-Regulation von Rezeptoren

21,23,25

Sachverzeichnis

{3-Rezeptorenblocker 293 - bei Akathisie 159 - bei Redeangst 36 - bei Tachykardien unter Antidepres-

siva 47 - als Tranquilizer 293 BewuBtseinsstorungen 385 bipolare affektive Psychose 110,111 Blickkrampf 158 Blutbildveriinderungen unter Neuro-

leptika 166 Blutdruckkrise, hypertonisch 97 Borderline-Perstinlichkeitsstorung

156 Bretazenil 247 Bromhamstoffderivate 327 Bromocriptin 165 Brueghel-Syndrom 161 Bulimie 36,76, 77 Butyrophenone 218

Carbamazepin 105,126 - bei Alkoholentzug 349 - antimanische Wirkung 127 - Behandlung des "rapid cycling" 127 - Kombination mit Lithium 111 - Phasenprophylaxe 127 - therapieresistente Schizophrenie

186 - Wirkungsmechanismus 129 Chinazolinonderivate 328 Chorea Huntington 161 Clonazepam 238 Clonidin 366 - Therapie bei Alkoholentzug 350 Clozapin 211 - Umstellung bei Therapieresistenz

185 COMT (Katecholamin-O-methyltrans­

ferase) 16, 139

Diimmerzustand 386 Dantrolen 165

Delir, pharmakogenes 387 delirante Syndrome 383 ff. Delirium tremens 348 8-9-Tetrahydrocannabinol (THC)

359 Demenz - Klassifikation 331 - Multiinfarktdemenz 331 Depolarisationsblock 145 Depotneuroleptika 181 ff.

Prophylaxe affektiver Psycho­sen 104

Depression - agitiert -iingstliche 30 - akinetische 170 - atypische 33, 93 - Azety1cholinhypothese 14 - Behandlung - - mit Benzodiazepinen 32 - - mit Neuroleptika 39 - gehemmte 30 - Gesamtbehandlungsplan 43 - Katecholaminhypothese 14 - Klassifikation 29 - korperlich begriindbare 44 - Langzeitbehandlung 43 - larvierte 31 - melancholischer Typ 31,33

415

- "pharmakogene" 32,156,169,170 - Phasenprophylaxe 111 - postpsychotische 170 - Prophylaxe mit Lithium 104 - psychotische 32, 40 - Rezidivverhiitung 43 - saisonale 41 - bei schirophrener Psychose 32 - Serotoninhypothese 14 - somatisierte 31 - therapieresistente 40, 41, 55 - unipolare 110 Desipraminbindungsstellen 25 Diabetes insipidus 116 Diiit - unter Lithium 115, 116 - tyraminarme, MAOH 92ff.

416

Diltiazem 162 Dimethyltryptamin 359 Diphenylbutylpiperidine 229 Diphenylmethanderivate 292 ff. Disulfiram 351 L-DOPA (3,4 Dihydroxyphenylala-

nin) 15 - Entzugssyndrom 165 Dopamin 139 - Abbau 139 - Rezeptoren 139 ff. dopaminerges System, Antidepres-

siva 24 Dreikomponentenschema 30 Dyskinesien - Friihdyskinesien 149, 157,374 - respiratorische 159,163 - Spatdyskinesien ("tardive dyskine-

sia") 148, ] 59ff., 374 - - AufkHirung 175 - - Therapie 162 dysthyme Stbrung 31

EEG, HypnotikaeinfluB auf Schlaf­EEG 302

Eifersuchtswahn, alkoholischer 350

EKB (Elcklrokrampfbehandlung) 120

- lhcrapicrcsislcnle Schizophrenic 186

Empfindlichkcitsvcranderungen von Rezeploren 21

Enlzugssyndrome 346ft. - Opiate 353, 354 Enuresis 64,76.77 Enzephalopathie. Wernicke- 350 Eosinophilic-Myalgie-Syndrom

27 Erregungszustande. psychomolori­

sche 378 Expressed-Emotion-Konzcpl 183 cxlrapyramidalmolorische Sympto­

me 134. 137. 156ff.

Sachvcrzeichnis

Fahrtauglichkeit - unter Antidepressiva 52 - unter Hypnotika 301,303 - unler Neuroleptika l70. l75 febrile Katalonie 164 .,Flashback"-Psychose 359,360 "Floppy-Infant" -Syndrom 259 Flumazenil 246, 247 Friihdyskinesien 149,157,374

GAB A (Gammaaminobuttersaure) 24, 242ff.

GABA-shift 246 gelemte Hilflosigkeit. Tiermodell der

Depression 13 generalisiertes Angstsyndrom 76 Gepiron 247 Gilles de la Tourette-Syndrom 161 Glomerulonephritis. unter Lithium

116 Grand mal-Anfiille unter Neurolepli­

ka 168

Haschisch 359 Hebephrenic 140 Heroin 352 Hilt1osigkeit. gelernte. Tiermodell der

Depression 13 Homovanillinsaure (HVS) 139 Horrorlrip 359.360 5-HTP (5-Hydroxylryplophan) 12 Huntington-Chorea 161 5- H ydroxyindolessigsaure (5- HIES)

17 S-Hydroxytryptophan (5-HTP) 12 8-Hydroxy-diaminopropyl-tctralin

(8-OH-DPAT) 241 hyperkinetisches Syndrom 376 Hyperthermie. maligne 164 Hypnolika 297ft. - EinfluB auf Schlaf-EEG - Fahrtauglichkcil 301, 303 - Halbwertszeiten 303

Sachverzeichnis

- Hangover-Effekte 303 - Kumulation 304 - Metabolisierung 302 - Risiken 299

Imidazopyridine 305 ff., 321 ff. Imipraminbindungsstellen 25 Injektion, Risiken bei Lv.-Injektio-

nen 168 Ipsapiron 247

lames-Lange-Theorie 294

Karbaminsiiurederivate 2% Kataplexie 67,68,76,77,376 Katatonie 153, 154 - Behandlung mit Lorazepam 153 - febrile 164 - pemiziose 153 Katecholamin-O-methyltransferase

(COMT) 16,139 Katecholaminhypothese, Depression

14 Klassifikation, Psychopharmaka 4 - funktionale 7 Koffein 375 kognitive Therapien 183 Kokain 357ff. Koma 386 Korsakow-Syndrom 350

L-DOPA 15 - Entzugssyndrom 164 L-Tryptophan 26, 55 larvierte Depression 31 Lichttherapie 41 Lithium - Akuttherapie der Manie 111 - antidepressive Wirkung 105 - Beeinflussung der zirkadianen

Rhythmik 109

417

- Behandlung der Manie 121 - Behandlungsdauer 122 - Diiit unter Lithium 115, 116 - Dosierung 120ff. - - Dosierungsintervall 121 - Elektrokrampfbehandlung 120 - Glomerulonephritis 116 - Indikationen 110 - Intoxikation 113,114 - klinische Pharmakologie 110 - Kombinationen - - mit Carbamezipin 111 - - mit Neuroleptika 111 - - mit Serotonin-Riickaufnahme-

hemmem 119 - Medikamentenwechselwirkungen

114,119 - Nierenfunktion 112, 116 - Nonresponse 127 - Phasenprophylaxe 111 - Schilddriisenfunktion 112 - Schwangerschaft 115 - Serumkonzentration 120ff. - Stillperiode 115 - teratogene Wirkung 109, 115 - bei therapieresistenter - - Depression 60 - - Schizophrenie 185 - Tremor unter Lithium 112 - Wechselwirkungen mit Antidepres-

siva 55 - Wirkungen - - auf Adenylatzyklase 106,107 - - auf Rezeptorsubsysteme 109 Lithiumsalze 123ff. "loading" 349 Lorazepam 281 - Katatoniebehandlung 153 "low-dose-dependence" 262 LSD (Lysergsiiurediiithylamid)

359

"major tranquilizer" 132 maligne Hyperthermie 164

418

maligncs ncuroleptisches Syndrom 163ff.

Manic 110, III - Behandlung mit Lithium 121 - - Akuttherapie 111 MAOH (Monoaminoxidasehemmer)

9, 13,91 ff. - bei atypischer Depression 34 - bei Bulimie 37 - irreversible 92 - bei Panikslbrung 33,93 - pharmakologisehe WirkungsqualiHi-

ten 13 - bei sozialer Phobie 36 - reversible 19,92 - Selektivitat 19 - bei Therapieresistenz 59 - tyraminarme Diat 92 ff. - Wechselwirkungen 54 - bei Zwangserkrankung 93 Marihuana 359 Meigc-Syndrom 161 melanozytenstimulicrendes Hormon

(MSH) 143 Mesealin 359 mesolimbisch-mesokortikales System

144 Methadon 354 "minor tranquilizer" 132 MiBbrauch 346ff. Monoaminoxidase, Enzymunterfor-

men 19 Monoaminoxidasehemmer

(s. MAOH) 9, 13 Morbus Parkinson (s. a. Parkinson­

Syndrom) 26 Morphin 352 M ultiinfarktdemenz 331

Nahrungsmittel, tyraminhaltige 19 Narkolepsie 67,68,76,77,376 neuroendokrinologische U ntersuchun-

gen, Antidepressiva 25 Neuroleptanalgesie 131

Sachverzeichnis

Neuroleptika 131 ff., 295 ff., 325, 369 - Abgrenzung gegen Tranquilizer und

Hypnotika 138 - Absetzen, intermittierendes 161 - akute/chronische Wirkungen 144fL - antidepressive Wirkung 39, 135,156 - Arzneimittelexantheme 167 - atypische 134, 137, 138, 145 - Blutbildkontrollen 173, 174 - Blutbildveranderungen 166 - Depotpraparate 181 ff. - bei Depression 32 - Dosierung 176 - Dosisanpassung 185 - Erhaltungsdosis 179 - Frtihintervention 180 - Grand mal-Anfalle 168 - Hochdosistherapie 178 - Indikationen 150ff. - Intervallbehandlung 180 - Kombinationen - - mit Elektrokrampfbchandlung

153,154 - - mit Lithium II I - Kontraindikationen 170 - Langzeitmedikation 155, 178,

180ff. - Nebenwirkungen, vegetative 165 - Persiinlichkeitsstiirungen 156 - - Borderline 156 - - schizotypische 156 - Pharmakokinetik 171 - Phasenprophylaxe affektiver Psy-

chosen 130 - Plasmaspiegel 176 - Prolaktinsekretion 169 - bei psychotischer Depression 32 - Routineuntersuchungen (tabellari-

sche Ubersicht) 174 - bei Schmerzsyndromen 38 - Schwangerschaft 175 - sexuelle Slbrungen 169 - Therapieresistenz 184 - Thrombosen 168 - als Tranquilizer 39,135,156

Sachverzeichnis

- Verkehrstiichtigkeit 170, 175 - Wechselwirkungen 170 - Wirkungsmechanismus 143ff. - Zielsymptome 151 - Zwangssyndrome 156 neuroleptische - Potenz 134 - Schwelle 179 Neurotransmitter, re-uptake 16 Neurotransmitter-Rezeploren, anti-

depressive Wirkung 20 nigrostriatiales System 144 Nikotin 360ft. Nikotin POaster 361 NMDA (N-Methyl-D-aspartat) 334 Non-Benzodiazepine, Hypnotika 305 Noradrenalin (NA) 12 - Abbau 16 - Ruckaufnahmehemmer 18 - Synthese 15 Nootropika 330ft. - Wirksamkeitsnachweis 332 - Wirkungsweise 334 Nuchtcrnhcitshilfe 355

8-0H-DPAT drug-discrimination test 241

Opiate 352 - Entzugssyndrom 353, 354 - Intoxikation 352 6strogene 40 Oxitriptan 26

Panikstbrung 67,68,76 - Benzadiazepintherapie 253 - Therapie mit MAOH 93 Paranoia 155 paranoid-halluzinatorische Psychose

155 Paraphilie 372 Parkinson, Morbus 26 Parkinson-Syndrom 148,149,158 - Antiparkinsonmittel 373 ft.

419

- pharmakogenes 148,149 pOanzliche Praparate 296,328 "pharmakogene" Depression 32, 156,

169,170 pharmakogenes Delir 387 pharmakologischer Tierversuch 4 "phase advance" 109 Phencyclidin 360 Phenothiazine 188 ff. - mit Piperazinylseitenkette 196 Phobie - einfache 36 - soziale 36, 93 Phosphatidylinositol-Stoftwechsel

107ft. Piperazinylseitenkette, Phenothia-

zine 196 Pisa-Syndrom 161 Placeboeffekt 1 ft. Polytoxikomanie 347 Positronen-Emissions-Tomographie

(PET) 4,150 Priapism us 372 Prodrug-Benzodiazepine 251,253 Prolaktin 143 Prolaktinsekretion unter Neuro-

leptika 169 Propranolol 38 - Therapie der Akathisie 159 protektive Kapazitat 330 psychiatrische Akutsituationen, Phar-

makotherapie 377 ff. psychomotorische Erregungs-

zustande 378 Psychopharmaka 3,4, 6 - Definition 3 - Klassifikation 4, 7 - - funktionale 7 - Wirksamkeitsnachweis 6 Psychostimulanzien 375 ft. Psychotherapie, interpersonale 42,

43 psychotische Depression 32 - Behandlung mit Neuroleptika 32 Psychotomimetika 358

420

Psylocin 359 Psylocybin 359

Rabbit-Syndrom 158 "rapid cycling" 49,111 Rauwolfia-Alkaloide 236 re-uptake von Neurotransmittern 16 Reboundinsomnie 302 REM (Rapid Eye Movement)-

Schlafphasen 26 Reserpin 132,149,187,236 respiratorische Dyskinesien 159,163 Rezeptoren - fJ-Down-Regulation 21,23,25 - Empfindlichkeitsveriinderungen 21

schizoaffektive Psychose, Phasenpro-phylaxe 105

schizoaffektive Psychose 110 Schizophrenia simplex 151 Schizophrenie 147 - Angehorigenarbeit 183 - Antidepressiva 186 - Benzodiazepine 186 - chronische 182 - Dopamin-Hypothese 150 - Glutamat-Hypothese 147 - Lebensqualitiit 183 - Priignanztypen 150, 154 - Rezeptorregulation 147 - Therapiepriidiktoren 184 - Therapieresistenz 178, 184ff. - - Carbamazepin 186 - - EKB 186 - - Lithium 185 - Verhaltenstherapie 186 Schlaf-EEG, Hypnotika 302 SchlafstOrungen, Ursachen 297 Schwangerschaft und Stillzeit - Antidepressiva 50 - Benzodiazepine 259 - Lithium 115 - Neuroleptika 175

Sachverzeichnis

"second messenger" 107 Serotonin - Abbau 17 - Riickaufnahmehemmer 84ff. - - Kombination mit Lithium 119 - - Nebenwirkungsprofil 48 - - Wechselwirkungen mit anderen

psychoaktiven Substanzen 54 - - bei PanikstOrung 34 - - bei Zwangserkrankung 35 - Synthese 17 Serotonin-Syndrom 55 Serotoninhypothese, Depression 14 sexuelle FunktionsstOrungen - Medikamente zur Behandlung

371 ff. - unter Neuroleptika 169 Single Photon Emission Compute-

rized Tomography (SPECT) 4 slow metabolizers 53 somatisierte Depression 31 Somnolenz 386 Sopor 386 Spiitdyskinesien (s. auch Dyskine­

sien) 149, 159ff., 374 Stillzeit (s. Schwangerschaft und Still-

zeit) Stoffwechsel, slow metabolizers 53 Struma 112 Stupor 152 Sucht 346 ff. Suizidalitiit 154, 381 - Benzodiazepintherapie 254 Sulpirid - antidepressive Wirkung 4, 39 Syndrome - Brueghei- 161 - delirante 383 ff. - Eosinophilie-Myalgie- 27 - Floppy-Infant- 259 - Gilles de la Tourette- 161 - hyperkinetisches 376 - Korsakow- 350 - malignes neuroleptisches 163 ff. - Meige-161

Sachverzeichnis

- Parkinson- 148, 149, 158 - Pisa- 161 - Rabbit-158 - Serotonin- 55 - Zungen-Schlund- 157, 158

"tardive dyskinesia" (Spatdyskine-sien) 148, J59ff., 374

Therapie, kognitive 183 Thiamin 350 Thioxanthene 204 Thrombophlebitiden 168 Thrombosen, unter Neuroleptika 168 Thymoleptikum 8 Thyreoidea-stimulierendes Hormon,

Thyreotropin (TSH) 107 Thyreotropin Releasing Hormone

(TRH) 26, 107 Tiaprid 163 Tiermodelle - Depression 11, 13 - - gelernte Hilflosigkeit 13 - Tranquilizer 240 Tranquilizerrrranquilizerwirkung

237ff. - Einteilung 239 - Neuroleptika 156

- Tiermodelle 240 Tremor unter Lithium 112 Trijodthyronin 40 trizyklische Antidepressiva (TZA)

8ff.,11 L-Tryptophan 26,55 tuberoinfundibulares System 144 tyraminhaltige Nahrungsmittel 19

Verhaltenstherapie 34, 36

421

- Schizophrenie 186 Verkehrstiichtigkeit s. Fahrtauglichkeit

Wernicke-Enzephalopathie 350

zirkadiane Rhythmik 109 Zungen-Schlund-Syndrom 157, 158 Zwangserkrankungen/Zwangssyn-

drome 35,67,68 - Behandlung - - mit MAOH 93 - - mit Neuroleptika 156 - - mit Serotonin-Riickaufnahme-

hemmern 35 Zyklopyrrolone 305ff.,319ff.

Pharmakaverzeichnis

In das Verzeichnis sind nur die im Handel befindlichen Praparate mit Handelsna­men und chemischen Kurzbezeichnungen (generic names) aufgenommen. Die chemischen Kurzbezeichnungen sind kursiv gedruckt. Als entbehrlich eingestufte und deshalb im Speziellen Teil nur in gekiirzter Form dargestellte Psychopharma­ka sind mit einem * gekennzeichnet.

Adumbran s. Oxazepam Akineton s. Biperiden Alimemazin* 188 Alprazolam 266 Alsadorm s. Doxylamin Amfetaminil 375 Amineurin s. Amitriptylin Amitriptylin 61 Amitriptylinoxid 65 AN 1 s. Amefetaminil Anafranil s. Clomipramin Androcur s. Cyproteronazetat Aneural s. Maprotilin Aponal s. Doxepin Aponeuron s. Amfetaminil Arminol s. Sulpirid Artane s. Trihexyphenidyl Atarax s. Hydroxyzin Atosil s. Promethazin Aurorix s. Moclobemid Avigilen s. Piracetam Azutranquil s. Oxazepam

Benperidol 218 Benzatropin 373 Bespar s. Buspiron

Betadorm s. Carbromal u. Diphen-hydramin

Bikalm s. Zolpidem Biperiden 373 Bromazanil s. Bromazepam Bromazepam 267 Bromisoval* 327 Bromperidol 220 Brotizolam 306 Buspiron 290 Buteridol s. Haloperidol

Calmonal s. Meclozin Captagon s. Fenetyllin Carbamazepin 126 Carbromal* 327 Cerebroforte s. Piracetam Cerebrosteril s. Piracetam Cerepar N s. Piracetam Chloraldurat s. Chloralhydrat Chloralhydrat 323 Chlordiazepoxid 269 Chlorprothixen 204. Ciatyl s. Clopenthixol Ciatyl-Z s. Zuclopenthixol Circanol s. Co-dergocrin

424

Circo-Maren s. Nicergolin Clobazam 271 Clomethiazol 362 Clomipramin 66 Clonidin 366 Clopenthixol 206 Clotiazepam 273 Clozapin 211 Co-dergocrin* 335 Cogentinol s. Benzatropin Contamex s. Ketazolam Cuxabrain s.Piracetam Cyclobarbital* 327 Cyproteronazetat 372

Dacoren s. Co-dergocrin Dalmadorm s. Flurazepam Dapotum s. Fluphenazin DCCK s. Co-dergocrin Decentan s. Perphenazin Defluina N s. Co-dergocrin Delgian s. Maprotilin Demetrin s. Prazepam Depressase s. Maprotilin Deprilept s. Maprotilin Desipramin 69 DH-Tox-Tablinen forte s. Co-dergo-

crin Diazepam 274 Dibenzepin 71 Dikaliumclorazepat 278 Diphenhydramin 324 Dipiperon s. Pipameron Distraneurin s. Clomethiazol Dixyrazin 196 Dociton s. Propanolol Dogmatil s. Sulpirid Dominal s.Prothipendyl Dormilfo M s. Meprobamat Dormo-Puren s. Nitrazepam Dormutil N s. Diphenhydramin Dosulepin* 72 Doxepin 73 Doxylamin 324

Pharmakaverzeichnis

Duracebrol s. Nicergolin Duradiazepam s. Diazepam Duralozam s. Lorazepam Duraperidol s. Haloperidol Durapitrop s. Piracetam Durazanil s. Bromazepam Durazepam s. Oxazepam

Eatan-N s. Nitrazepam Encephabol s. Pyritinol Encetrop s. Piracetam Equilibrin s. Amitriptylinoxid Ergobel s. Nicergolin Ergocalm s. Lormetazepam Ergodesit s. Co-dergocrin Ergoplus s. Co-dergocrin Esucos s. Dixyrazin Eunerpan s. Me1peron Eusedon mono s. Promethazin Exphobin N s. Meprobamat

Fenetyllin 375 Fevarin s. Fluvoxamin Fluanison* 221 Fluanxol s. Flupentixol Fluctin s. Fluoxetin Fluninoc s. Flunitrazepam Flunitrazepam 308 Fluoxetin 84 Flupentixol 208 Fluphenazin 196 Flurazepam 310 Fluspirilen 229 Fluvoxamin 87 Fokalepsin s. Carbamazepin Frisium s. Clobazam

Gamonil s. Lofepramin Gingium s. Ginkgo biloba Ginkgo 405 s. Ginkgo biloba Ginkgo biloba* 337 Ginkobil ratiopharm s. Ginkgo biloba

Pharmakaverzeichnis

Gittalun s. Doxylamin Gityl s. Bromazepam Glianimon s. Benperidol Guaifenesin* 296

Halcion s. Triazolam Haldol s. Haloperidol Haloperidol 221 Hoggar N s. Doxylamin Hopfen- und Baldrianpraparate*

329 Hydergin s. Co-dergocrin Hydro-Cebral-ratiopharm s. Co-dergo­

crin Hydroxyzin* 292 Hypnorex retard s. Lithiumkarbo­

nat

Idom s. Dosulepin Imap s. Fluspirilen Imeson s. Nitrazepam Imipramin 75 Impromen s. Bromperidol Insidon s. Opipramol

Jatroneural s. Trifluoperazin Jatrosom N s. Tranylcypromin

Kanopan s. Maprotilin D,L-Kavain* 296 Kaveri s. Ginkgo biloba Ketazolam 280

Lamra s. Diazepam Laroxyl s. Amitriptylin Laubeel s. Lorazepam Lendormin s. Brotizolam Leponex s. Clozapin Leukominerase s. Lithiumkarbonat Levomepromazin 188

Lexotanil s. Bromazepan Li 450 "Ziethen" s. Lithiumkarbo­

nat

425

Librium s. Chlordiazepoxid Limbatril s. Amitriptylin u. Chlordia­

zepoxid Lithium "Apogepha" s. Lithium-

karbonat Lithium-Duriles s. Lithiumsulfat Lithiumaspartat* 123 Lithiumazetat 123 Lithiumkarbonat 124 Lithiumorotat 125 Lithiumsulfat 126 Lofepramin* 77 Longopax s. Amitriptylin u. Perphena-

zin Loprazolam 312 Loretam s. Lormetazepam Lormetazepam 313 Ludiomil s. Maprotilin Luminal s. Phenobarbital Lupovalin s. Diphenhydramin Lyogen s. Fluphenazin Lyorodin s. Fluphenazin

Mapro-Gry s. Maprotilin Maprolu s. Maprotilin Mapro-Tablinen s. Maprotilin Maprotilin 78 Masmoran s. Hydroxyzin Meclozin 324 Medinox Mono s. Pentobarbital Melleril s. Thioridazin Melperon 226 Memo-Puren s. Piracetam Memoq s. Nicergolin Meprobamat* 296 Meresa s. Sulpirid Metaclazepam 284 Methaqualon* 328 Methylphenidat 375 Mianserin 98 Mirpan s. Maprotilin

426

Moclobemid 91 Mogadan s. Nitrazepam Mono Demetrin s. Prazepam Multum s. Chlordiazepoxid

Naltrexon 355 Nehydrin N s. Co-dergocrin Nemexin s. Naltrexon Neo-OPT s. Bromazepam Neodorm s. Pentobarbital Neogama s. Sulpirid Nervolitan S s. Phenobarbital Nervo-OPT-N s. Diphenhydramin Neurocil s. Levomepromazin Neuronika s. D,L-Kavain Nicergolin* 339 Nicerium s. Nicergolin Nicotinell TTS s. Nikotinpflaster Nikofrenon s. Nikotinpflaster Nikotinpflaster 361 Nimodipin 340 Nimotop s. Nimodipin Nipolept s. Zotepin Nitrazepam 315 Noetamid s. Lormetazepam Noetazepam s. Oxazepam Nootrop s. Piraeetam Norkotral N s. Pentobarbital Normabrain s. Piraeetam Normi-Nox s. Methaqualon Normoe s. Bromazepam Nortrilen s. Nortriptylin Nortriptylin 81 Novanox s. Nitrazepam Noveril s. Dibenzepin Novoeetam 800 s. Piraeetam Novofluen s. Co-dergoerin Novoproteet s. Amitriptylin

Omea s. Fluphenazin Opipramol 294 Orap s. Pimozid Orhinamon s. Tiotixen

Pharmakaverzcichnis

Orphol s. Co-dergoerin Oxa-Puren s. Oxazepam Oxazepam 285 Oxazolam 287

Paracefan s. Clonidin Pamate s. Tranylcypromin Paroxetin 89 Pemolin 375 Pentobarbital* 327 Perazin 200 Perphenazin 201 Pertofran s. Desipramin Phenaemal s. Phenobarbital Phenobarbital* 327 Phenprobamat* 296 Pimozid 231 Pipamperon 227 Piraeebral s. Piraeetam Piracetam* 343 Planum s. Temazepam Praxiten s. Oxazepam Prazepam 289 Prism a s. Mianserin Pro Dorm s. Lorazepam Promazin* 191 Promethazin 191 Promkiddi s. Promethazin Propanolol 293 Protaetyl s. Promazin Prothazin liquidum s. Prometha-

zin Prothipendyl 215 Psymion s. Maprotilin Psyquil s. Triflupromazin Punktyl s. Lorazepam Pyritinol* 345

Quilonum retard s. Lithiumkar­bonal

Quilonum s. Lithiumazetat

Pharmakaverzeichnis

Remestan s. Temazepam Remoxiprid 232 RepeItin s. Alimemazin Repocal s. Pentobarbital Reserpin* 236 Ritalin s. Methylphenidat Rohypnol s. Flunitrazepam Rokan s. Ginkgo biloba Roxiam s. Remoxiprid

S.8 Tabletten s. Diphenhydra-min

Saroten s. Amitriptylin Sedalande s. Fluanison Sedaplus s. Doxylamin Sediat s. Diphenhydramin Sedopretten s. Diphenhydramin Sedovegan s. Diphenhydramin Sekundal D s. Diphenhydramin Senior 20 s. Pemolin Sermion s. Nicergolin Seroxat s. Paroxetin Sigacalm s. Oxazepam Sigaperidol s. Haloperidol Sinquan s. Doxepin Sirtal s. Carbamazepin Somagerol s. Lorazepam Somnium forte s. Carbromal Somnupan C s. Cyclobarbital Sonin s. Loprazolam Speda s. Vinylbital Sponsin s. Co-dergocrin Stangyl s. Trimipramin Staurodorm Neu s. Flurazepam Steno-Valocordin s. Bromisoval u.

Phenobarbital Stesolid s. Diazepam Stilnox s. Zolpidem Sulpirid 234

Tafil s. Alprazolam Tagonis s. Paroxetin Talis s. Metaclazepam

Taractan s. Chlorprothixen Tavor s. Lorazepam Taxilan s. Perazin Tebonin s. Ginkgo biloba Tegretal s. Carbamazepin Temazepam 317 Tesoprel s. Bromperidol Theralene s. Alimemazin Thioridazin 194 Thombran s. Trazodon Timonil s. Carbamazepin Tiotixen* 211 Tisercin s. Levomepromazin Tofranil s. Imipramin Tolid s. Lorazepam Tolvin s. Mianserin Tradon s. Pemolin Tranquase s. Diazepam Tranquit s. Oxazolam Tranquo-Tablinen s. Diazepam Tranxilium s. Dikaliumclor-

azepat Tranylcypromin 94 Trazodon 100 Trecalmo s. Clotiazepam Triazolam* 318 Trifluoperazin* 203 Trifluperidol* 229 Tri[lupromazin* 193 Trihexyphenidyl 373 Trimipramin 83 Triperidol s. Trifluperidol Truxal s. Chlorprothixen

Urbilat s. Meprobamat Uskan s. Oxazepam

Valaxona s. Diazepam

427

Valdispert s. Hopfen-und Baldrianprii-parate

Valium s. Diazepam Valiquid s. Diazepam Valocordin N s. Phenobarbital

428

Viloxazin 102 Vinylbital* 327 Visano N s. Meprobamat Vivalan s. Viloxazin

Ximovan s. Zopiclon

Pharma

Yocon-Glenwood s. Yohim Yohimbin 371

Zolpidem 321 Zopiclon 319 Zotepin 216 Zuclopenthixol 207

Handelsnamenverzeichnis Osterreich/Schweiz*

Das Verzeichnis enthiilt nur Priiparate, die in Osterreich und in der Schweiz unter eigenem HandeIsnamen im Verkehr sind. Priiparate, die im jeweiligen Speziellen Teil nicht besprochen werden, sind hier nicht aufgefuhrt. Die chemischen Kurzbe­zeichnungen sind kursiv gedruckt (Seitenzahlen s. Pharmakaverzeichnis).

Zusiitze zu Markennahmen wie "forte", "mite", "retard" etc. wurden weggelassen (Ausnahme: Lithiumpriiparate). Kombinationspriiparate sind nicht aufgefiihrt.

Ambivalon (CH) s. Amitriptylinoxid Anxiolit (A,CH) s. Oxazepam

Biokawa (CH) s. Kavain Buronil (A) s. Melperon Buspar (A,CH) s. Buspiron

Calepsin (CH) s. Carbamazepin Catapresan (A,CH) s. Clonidin Cisordinol (A) s. Clopenthixol Clopixol (CH) s. Zuclopenthixol Cyrpon (A) s. Meprobamat

Dialag (CH) s. Diazepam

Epikur (A) s. Meprobamat Ergotop (A) s. Nicergolin

F10xyfral (A,CH) s. Fluvoxamin F1uctine (A,CH) s. Fluoxetin

Gewacalm (A) s. Diazepam

Hemineurin (CH) s. Clomethiazol Hypnorex (CH) s. Lithiumkarbonat

Lendorm (A) s. Brotizolam Levanxol (A) s. Temazepan Lithiofor (CH) s. Lithiumsulfat Loramet (CH) s. Lormetazepam Lorasolid (CH) s. Lorazepam

Meprodil (CH) s. Meprobamat Merlit (A) s. Lorazepam Microbamat (A,CH) s. Meprobamat Miltaun (A) s. Meprobamat Minozinan (CH) s. Levomepromazin Moditen (CH) s. Fluphenazin Mogadon (A,CH) s. Nitrazepam Mosaro (A) s. Kavain

Neurolepsin (A) s. Lithiumkarbonat Neurotop (A) s. Carbamazepin Noctamid (A) s. Lormetazepam Nootropil (A,CH) s. Piracetam

* Fur die Hilfe bei der Erstellung des Handelsnamenverzeichnisses danken wir Frau Dr. E.Holsboer-Trachsler, Basel, und Herro Univ.-Doz. Dr. W.Fleischhacker, Innsbruck.

430

Nonnison (CH) s. Temazepam Nozinan (A,CH) s. Levomepromazin

Paceum (CH) s. Diazepam Petranquil (A) s. Meprobamat Phenergan (CH) s. Promethazin Praxiten s. Oxazepam Prazine (CH) s. Promazin Protiaden (CH) s. Dosulepin Psychopax (A,CH) s. Diazepam

Ouilonorm (A,CH) s. Lithiumacetat Ouilonorm retard (A,CH) s. Lithium­

karbonat

Resyl (A,CH) s. Guaifenesin

Sedazin (CH) s. Lorazepam Seresta (CH) s. Oxazepam Serpasil (CH) s. Reserpin

Handelsnamenverzeichnis Osterreich/Schweiz

Sinequan (A) s. Doxepin Solatran (CH) s. Ketazolam Somnubene (A) s. F/unitrazepam Stesolid (A,CH) s. Diazepam Surrnontil (CH) s. Trimipramin

Tegretol (A,CH) s. Carbamazepin Temesta (A,CH) s. Lorazepam Tolvon (A,CH) s. Mianserin Trilafon (CH) s. Perphenazin Trittico (A,CH) s. Trazodon Tryptizol (A) s. Amitriptylin

Umbrium (A) s. Diazepam Urbanyl (CH) s. Clobazam Uskan (CH) s. Oxazepam

Xanax (CH) s. Alprazolam Xanor (A) s. Alprazolam